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Abstract——Injury to or disease of the nervous system
can invokechronicandsometimes intractableneuropathic
pain. Many parallel, interdependent, and time-dependent
processes, including neuroimmune interactions at the
peripheral, supraspinal, and spinal levels, contribute to
the etiology of this “disease of pain.” Recent work
emphasizes the roles of colony-stimulating factor 1, ATP,
and brain-derived neurotrophic factor. Excitatory
processes are enhanced, and inhibitory processes are
attenuated in the spinal dorsal horn and throughout the
ABBREVIATIONS: AMPA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AT2, angiotensin receptor type 2; BCH,
2-(-)-endoamino-bicycloheptene-2-carboxylic acid; BDNF, brain-derived neurotrophic factor; Cav1, Cav2, Cav3, voltagae gated Ca2
+ channels
types 1, 2 and 3; CB2, cannabinoid receptor 2; CCI, chronic constriction injury; CCL, chemokine (C-C motif) ligand; CNS, central nervous
system; CSF-1, colony-stimulating factor 1; DRG, dorsal root ganglion; EAAT2, excitatory amino acid transporter 2; GBP, gabapentin; GLT-1,
glutamate-transporter-1; HCN, hyperpolarization-activated cyclic nucleotide gated; HVA, high voltage activated; IB4, isolectin B4; ICa,
calcium channel current; IL, interluekin; KCC2, potassium-chloride exporter 2; LTP, long-term potentiation; LVA, low voltage activated;
mEPSC, miniature excitatory postsynaptic current; MIDAS, metal ion-dependent adhesion site; Nav1.7, Nav1.8, Nav1.9, voltage gated sodium
channels types 1.7, 1.8 and 1.9; NMDA, N-methyl D-aspartate; NPY, neuropeptide Y; P2X4R, purinergic ionotropic receptor 2X4; PGB,
pregabalin; sEPSC, spontaneous excitatory postsynaptic current; STOML-3, stomatin-like protein 3; TLR5, Toll-like receptor 5; TNF, tumor
necrosis factor; TrkB, tropomyosin receptor kinase B; TRP, transient receptor potential; TRPM8, TRP channel type M8; TRPV1, TRP channel
type V1; TSP, thrombospondin; VGCC, voltage-gated calcium channel; VNUT, vesicular nucleotide transporter; VWA, VonWillebrand Factor A.
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somatosensory system. This leads to central sensitization
and aberrant processing such that tactile and innocuous
thermal information is perceived as pain (allodynia).
Processes involved in the onset of neuropathic pain
differ from those involved in its long-term maintenance.
Opioids display limited effectiveness, and less than 35% of
patients derivemeaningful benefit fromother therapeutic
approaches.We thus reviewpromising therapeutic targets
thathaveemergedover the last 20years, includingNa+,K+,
Ca2+, hyperpolarization-activated cyclic nucleotide–gated
channels, transient receptor potential channel type V1
channels, and adenosine A3 receptors. Despite this
progress, the gabapentinoids retain their status as
first-line treatments, yet their mechanism of action is
poorly understood. We outline recent progress in
understanding the etiology of neuropathic pain and
show how this has provided insights into the cellular
actions of pregabalin and gabapentin. Interactions of
gabapentinoids with the a2d-1 subunit of voltage-gated
Ca2+ channels produce multiple and neuron type-
specific actions in spinal cord and higher centers. We
suggest that drugs that affect multiple processes, rather
than a single specific target, show the greatest promise
for future therapeutic development.
I. Introduction
A. Clinical Presentation and Pharmacotherapy of
Neuropathic Pain
Pain is the most common reason for people to seek
medical attention (Salter, 2014). Despite this, nocicep-
tive pain is a vital physiologic process that signals
actual or potential tissue damage (Iadarola and Caudle,
1997). By so doing, it protects the individual from injury
and secures the survival of the species. By contrast,
direct injury to neural tissue can produce nerve or
neuropathic pain that lasts for months or years after
any injury has healed (Costigan et al., 2009b; Moulin
et al., 2014). Exact prevalence of neuropathic pain
within the global population is unknown, but most
studies put estimates at between 1.5% and 8%, equating
to between 100 million and 560 million people world-
wide (Gilron et al., 2006; Torrance et al., 2006, 2013;
Salter, 2014; Bouhassira and Attal, 2016).
Neuropathic pain is defined formally as “pain caused
by a lesion or disease of the somatosensory system”
(Jensen et al., 2011). It can be caused by traumatic
nerve, spinal cord, or brain injury (including stroke) or
can be associated with diabetic, human immunodefi-
ciency virus/AIDS, and postherpetic neuropathies, or
with multiple sclerosis (Treede et al., 2008) or cancer,
and/or the toxic effects of chemotherapeutic agents
(Xiao et al., 2007; Schmidt et al., 2010).
Clinical diagnosis of neuropathic pain depends on
evaluation of the following criteria: 1) pain with a
distinct neuroanatomical distribution, 2) a medical
history that suggests a lesion or disease of the nervous
system, 3) a confirmatory test to demonstrate neuroan-
atomical distribution, and 4) a confirmatory test to
demonstrate a lesion or disease of the nervous system
(Treede et al., 2008). Definite neuropathic pain is
categorized as fulfilling all of these criteria, whereas
probable neuropathic pain is categorized as fulfilling
criteria 1 and 2 without evidence from 3 to 4. There has
been an increasing awareness of neuropathic pain in the
scientific literature over the past 40 years, suggesting
that it is more commonplace than previously thought.
The prevalence of the phrase neuropathic pain in books
as measured using Google “Ngram” Viewer has in-
creased more than fourfold between 1992 and 2008.
The various manifestations of neuropathic pain are
notoriously resistant to the actions of nonsteroidal anti-
inflammatory drugs and opioids (Yekkirala et al., 2017).
In stark contrast to the profound effectiveness of opioids
in nociceptive pain, there is no similar panacea for the
treatment of neuropathic pain. Any pain that is opioid
resistant is likely neuropathic. A recent meta-analysis
of clinical trial data (Finnerup et al., 2015) supported
theuseof tricyclic antidepressants, serotonin–noradrenaline
uptake inhibitors such as duloxetine and the gabapen-
tinoids, pregabalin (PGB), and gabapentin (GBP) as
first-line treatments. Tramadol and controlled-release
opioids are recommended as second-line treatments
and cannabinoids as third-line treatments. Fourth-
line treatments include methadone, lamotrigine, laco-
samide, tapentadol, and botulinum toxin (Moulin et al.,
2014). Other drugs in current clinical use include
carbemazepine, lidocaine patch, capsaicin patch, and
ziconotide (Table 1).
Barriers to the development of effective new treat-
ments include the diversity of pathophysiological situ-
ations, different pain etiologies, genetic predispositions
(Mogil, 2012a; Zorina-Lichtenwalter et al., 2016; Sexton
et al., 2017), and different ethnicities (Hastie et al.,
2012) encountered in the clinic. This is compounded by
epigenetic modifications in humans (Stone and Szyf,
2013) and by the limited ability of rodent models to
predict clinical efficacy (Mogil, 2017; Patel et al., 2017;
Sexton et al., 2017; Yekkirala et al., 2017). Despite the
realization that pain processing in males differs from
that in females (Mogil, 2012b; Mifflin and Kerr, 2013;
Sorge et al., 2015; Dodds et al., 2016; Melchior et al.,
2016; Dickie et al., 2017; Sorge and Totsch, 2017), many
preclinical studies have been done on male rodents to
avoid possible complications imposed by the estrous
cycle. It is also established that neonatal injury can
affect manifestation of pain in adults (Beggs et al.,
2012a). Lastly, ongoing and/or paroxysmal stimulus-
independent pain is amajor issuewith patients, but this
is difficult to assess in animal models (Calvo et al.,
2012).
Despite these issues, recent advances in understand-
ing the etiology of neuropathic pain have paved the way
for development of new therapeutic approaches. At
present, however, none of these rationally developed
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compounds have attained the status of monoamine
uptake inhibitors and gabapentinoids as first-line
treatments. Several reviews of the pharmacotherapy
of neuropathic pain have appeared in the last few years;
some are broadly based (Kremer et al., 2016; Yekkirala
et al., 2017), whereas others discuss the use of specific
agents such as cannabinoids (Luongo et al., 2017),
amitriptyline (Moore et al., 2015), Ca2+ and/or Na+
channel blockers (Waxman and Zamponi, 2014;
Zamponi et al., 2015; Patel et al., 2017), and agents
that potentiate GABAergic inhibition (Zeilhofer et al.,
2012a).
Because gabapentinoids were originally developed as
anticonvulsant agents (Offord and Isom, 2015), much is
still to be learned about the mechanism of their anti-
allodynic effect (Bannister et al., 2017b). This means
that the drugs that are used most frequently are the
least well understood. In the following sections, we will
overview recent advances in understanding the etiology
of pain and how it has led to rational drug development
and to a further, yet incomplete, understanding of
gabapentinoid action.
B. Organization of the Spinal Dorsal Horn
Although a full description of the organization of the
dorsal horn is beyond the scope of the present review,
the following paragraphs provide background to recent
advances in the understanding of spinal mechanisms
that initiate neuropathic pain. We will show how these
insights have led to the identification of therapeutic
targets and to improved understanding of gabapenti-
noid action. For additional information on dorsal horn
organization and nociceptive processing, the reader is
referred to recent reviews (Braz et al., 2014; Peirs et al.,
2015; Cordero-Erausquin et al., 2016; Peirs and Seal,
2016; Abraira et al., 2017; Todd, 2017) and original
papers (Lu and Perl, 2003, 2005; Santos et al., 2007;
Yasaka et al., 2010).
Tissuedamage orperturbation capable of causingpain is
detected by free nerve endings in peripheral and visceral
structures and relayed by first-order sensory neurons
(primary afferents) to second-order sensory neurons in
the dorsal horn of the spinal cord. Glutamate and neuro-
peptides such as substance P and calcitonin gene-related
peptide mediate neurotransmission between primary af-
ferent and second-order sensory neurons. Glutamate
interacts with Ca2+-permeable and Ca2+-impermeable
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) and with N-methyl D-aspartate (NMDA) re-
ceptors, but not with kainate receptors (Tong and
MacDermott, 2006). The cell bodies of first-order
sensory neurons reside in the dorsal root ganglia
(DRG).
Although all primary afferent neurons are widely
believed to be glutamatergic (West et al., 2015), it has
been suggested that GABA-mediated inhibitory inter-
actions may play a role in nociceptive processing at the
level of the DRG (Du et al., 2017). If these findings are
verified, they will provoke considerable debate and
reassessment of current ideas of sensory and nocicep-
tive processing. It is possible that primary afferent
neurons release GABA from their cell bodies in DRG,
yet release glutamate from their terminals in the spinal
cord.
The gray matter of the spinal cord is divided into the
10 laminae of Rexed (Fig. 1A) (Rexed, 1952). Nociceptive
information is received in lamina I, lamina II (substan-
tia gelatinosa; Fig. 1, A and B), and, to a lesser extent,
TABLE 1
Drugs currently used in the clinical management of neuropathic pain
Drug Target Status
Gabapentinoids (pregabalin,
gabapentin)
a2d21 auxiliary subunit of voltage-gated Ca2+
channels
First-line treatment (Finnerup et al., 2015)
Tricyclic antidepressants
(amitriptyline)
Noradrenaline/Serotonin uptake systems First-line treatment (Finnerup et al., 2015)
Noradrenaline/Serotonin uptake
inhibitors (duloxetine)
Noradrenaline/Serotonin uptake systems First-line treatment (Finnerup et al., 2015)
Tramadol Opioid receptors and noradrenaline/serotonin
uptake systems
Second-line treatment (Moulin et al., 2014)
Controlled release opioids Opioid receptors Second-line treatment (Moulin et al., 2014)
Cannabinoids CB1 and CB2 receptors Third-line treatment (Moulin et al., 2014)
Botulinum toxin Neurotransmitter release Fourth-line treatment (Moulin et al., 2014)
Methadone Opioid and NMDA receptors Fourth-line treatment (Moulin et al., 2014)
Lamotrigine Voltage-gated Na+ channels; L-, P-, and N-type Ca2+
channels
Fourth-line treatment (Moulin et al., 2014)
Lacosamide Slow inactivation of voltage-gated Na+ channels Fourth-line treatment (Moulin et al., 2014)
Tapentadol m-Opioid receptors and noradrenaline uptake
system
Fourth-line treatment (Moulin et al., 2014)
Carbemazepine Voltage-gated Na+ channels and GABAA receptors Use primarily restricted to trigeminal neuralgia
(Demant et al., 2014)
Ziconotide (synthetic v-conotoxin
MVIIA)
N-type voltage-gated Ca2+ channels Administered intrathecally when other treatments
fail (McGivern, 2007)
Ketamine NMDA receptors Sometimes used clinically (Niesters et al., 2014;
Maher et al., 2017)
Lidocaine patch Voltage-gated Na+ channels In clinical use (Finnerup et al., 2015)
Capsaicin patch TRPV1 channels In clinical use (Dworkin et al., 2007)
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laminaV (Todd, 2010; Zeilhofer et al., 2012b;West et al.,
2015; Peirs and Seal, 2016). Although lamina I contains
interneurons for modulation and projection neurons for
transmission of nociceptive information, lamina II
contains mainly interneurons that project to lamina I.
In spite of its importance, there is still very much that is
unknown about dorsal horn circuitry and how it relates
to the pathophysiology of chronic pain (Sandkuhler,
2009; Todd, 2010; Prescott et al., 2014; Peirs and Seal,
2016). Aspects of dorsal horn physiology and organiza-
tion that are salient to pain etiology, drug development,
and gabapentinoid action are described below.
1. Lamina I/Marginal Zone. This contains both
interneurons and projection neurons and receives in-
puts from Ad- and C-peptidergic primary afferents
fibers (Torsney, 2011; Cordero-Erausquin et al., 2016)
(Fig. 1C). Ad fibers convey the immediate first pain
evoked by tissue injury. Peptidergic afferent fibers,
which contain substance P and calcitonin gene-related
peptide, are involved in transmitting the second pain
that results from injury-induced inflammation. Unlike
non-nociceptive C fibers, they do not bind the plant
isolectin B4 (IB4) (Stucky and Lewin, 1999; Fang et al.,
2006) and instead express transient receptor potential
(TRP) channel type V1 (TRPV1) channels, tropomyosin
receptor kinaseAneutrophin receptors, and voltage-gated
sodium channel type 1.9 (Nav1.9) tetrodotoxin-resistant
Na+ channels (Fang et al., 2002). Lamina I also receives
input from excitatory vertical cells in lamina II. Output
neurons to higher centers express neurokinin NK1 recep-
tors (Yu et al., 2005) that are activated by substance P
(Fig. 1C).
2. Lamina II/Substantia Gelatinosa. Unlike lam-
ina I, lamina II does not contain neurons that project
directly to higher centers (Fig. 1C). It is divided into
three sublaminae.
a. Laminar IIo (outer). Laminar IIo (outer) receives
glutamatergic nociceptive input from lamina I aswell as
polysynaptic input from deeper laminae. It contains
glutamatergic stalked or vertical cells (Fig. 1C), which
project back to lamina I and typically display a delayed
firing pattern in response to a depolarizing current
command (Yasaka et al., 2010). Their dendrites pene-
trate deeper regions of lamina II and lamina III (Todd,
2010; Peirs and Seal, 2016). Another population of
excitatory neurons known as central cells expresses
short (,400 mm) rostrocaudal projections (Todd, 2010,
2017) (Fig. 1C).
Inhibitory interneurons in lamina IIo typically dis-
play a tonic discharge pattern and islet cell morphology
and project rostrocaudally for 400 mm or more (Grudt
and Perl, 2002; Todd, 2010). They receive some of their
excitatory synaptic input from non-nociceptive, rapidly
conducting Ab fibers (Daniele and MacDermott, 2009),
and this may provide a cellular basis for the attenuation
of pain by activation of innocuous sensory pathways
(Zeilhofer et al., 2012b). It is likely that islet cell
terminals release both glycine and GABA and that both
neurotransmitters may be packaged in the same vesi-
cles (Keller et al., 2001).
b. Lamina IIid (inner dorsal). Neurons in lamina IIid
receive direct input from C nonpeptidergic afferents (Lu
and Perl, 2003; Cordero-Erausquin et al., 2016)
(Fig. 1C). These afferents generally do not convey
nociceptive information and bind the plant isolectin
Fig. 1. (A) Rexed laminae of the spinal cord. Laminae I and II form the
marginal zone and substantia gelatinosa, respectively, and together these
make up the superficial dorsal horn. Within the dorsal horn, Ab tactile
and hair afferents end mainly in laminae III–VI with some extension into
lamina IIi with distribution dependent on function. Ad hair-follicle
afferents extend across the lamina II/III border. Ad nociceptors end
mainly in lamina I, occasionally branching to laminae V and X.
Peptidergic, nociceptive C fiber afferents synapse mainly in lamina I
and IIo. Nonpeptidergic C fibers occupy the inner part of lamina II. (B)
Acutely isolated spinal cord slice from a 30-day-old rat. The substantia
gelatinosa is clearly visible as a translucent band under infrared
differential interference contrast optics. (C) Diagram to illustrate the
principal synaptic connections in the superficial dorsal horn. From Peirs
and Seal (2016). Reprinted with permission from American Association
for the Advancement of Science.
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IB4. They express P2X3 receptors for ATP and the
RET–tyrosine kinase–GFRa receptor complex for glial
cell line–derived neurotrophic factor (Molliver et al.,
1997).
c. Lamina IIiv (inner ventral). Lamina IIiv (inner
ventral) contains excitatory interneurons that express
calretinin or protein kinase Cg (Peirs and Seal, 2016).
Immunohistochemical staining for this layer of protein
kinase Cg–expressing neurons has been used to define
the boundary between lamina II and III (Hughes et al.,
2003; Stebbing et al., 2016; Boyle et al., 2017).
3. Lamina III. This receives peripheral input from
Ab/Ad myelinated or lightly myelinated primary affer-
ents (Fig. 1C). Inputs project to parvalbumin-containing
inhibitory GABA/glycinergic neurons and to excitatory
interneurons. NR1-expressing projection neurons also
reside in lamina III (Todd, 2010).
4. Laminae IV, V, and VI. These laminae contain
wide dynamic range (projection) neurons that receive
direct Ab fiber input from primary afferents as well as
polysynaptic inputs that convey nociceptive information
from superficial laminae (Peirs and Seal, 2016). Their
rate of discharge is thus correlated to the type of input,
with painful sensation eliciting high frequency dis-
charge and innocuous stimuli generating more modest
discharge (Dalal et al., 1999). These laminae are in-
volved in the complex processing of tactile information
such as object size, shape, texture as well as vibration,
and direction of stimulus movement. This encoded
information is relayed to higher centers (Abraira
et al., 2017).
II. Mechanisms of Neuropathic Pain and
Potential Therapeutic Targets
Neuropathic pain is a maladaptive response of the
nervous system to damage. The signs and symptoms
include allodynia (pain in response to an innocuous
stimulus), hyperalgesia (increased pain response to a
noxious stimulus), spontaneous pain (electric-shock–
like or shooting pain), and, occasionally, causalgia or
incessant burning pain (Costigan et al., 2009b). Some
patients experience anesthesia dolorosa or loss of
sensation, but persistence of pain from the site of injury
(Wall et al., 1979). Neuropathic pain is also seen in
complex regional pain syndromes I and II as a result of
neurogenic inflammation and/or pathologic cross talk
between sensory and sympathetic nerves (Abdulla and
Smith, 1997; McLachlan and Hu, 1998; Yen et al., 2006;
Calvo et al., 2012; Magnussen et al., 2015). For these
reasons, neuropathic pain is often referred to as the
“disease of pain.” Neuropathic pain is marked by
changes in normal sensory signaling at the level of the
periphery, spinal cord, and brain (thalamus and cortex)
that occur over the course of weeks or months. These
lead to alterations in genomic expression and differ-
ences in cortical structures (Costigan et al., 2009b;
Sandkuhler, 2009; Alvarado et al., 2013; Tajerian
et al., 2013, 2014; Luo et al., 2014). Thus, the patho-
physiological changes responsible for the onset of
neuropathic pain are distinct from those responsible
for its chronic presentation. This distinction between
the onset phase and the maintenance phase of neuro-
pathic pain becomes particularly relevant when
attempting to relate findings in animal models with
the presentation of pain in the clinic. Many animal
studies relate to pain onset and do not address the long-
term persistence of pain, which is more relevant to the
clinical situation.
This review concentrates on neuropathic pain as
generated by peripheral nerve injury, as this is the
focus of most experimental studies (Kim et al., 1997;
Decosterd and Woolf, 2000; Calvo et al., 2012;
Stemkowski and Smith, 2013). It has been suggested,
however, that injury to the spinal cord per se may
engage peripheralmechanisms to generate chronic pain
(Yang et al., 2014b). In the clinic, peripheral nerve
injury can reflect traumatic injury but is more fre-
quently a consequence of diabetic-, postherpetic-, or
human immunodeficiency virus–related neuropathies
or complex regional pain syndromes I or II. In all
situations, release of inflammatory mediators at the
site of injury triggers alterations in the properties of
primary afferent neurons (Watkins and Maier, 2002;
Scholz and Woolf, 2007). Their excitability is increased,
and this leads to the appearance of ectoptic, stimulus-
independent activity (Wall and Devor, 1983). This
altered activity results from changes in the properties
and/or expression of various types of voltage-gated Na+,
K+, and Ca2+ channels (Waxman et al., 1999; Abdulla
and Smith, 2001b, 2002; Cummins et al., 2001;
Stemkowski and Smith, 2012b; Bourinet et al., 2014;
Waxman and Zamponi, 2014; Daou et al., 2016). There
are also changes in the function of Na+-K+ ATPases
(Venteo et al., 2016), intracellular Ca2+ handling
(Hogan et al., 2014; D’Arco et al., 2015; Yilmaz and
Gold, 2016; Yilmaz et al., 2017), TRP channels (Basso
and Altier, 2017), and hyperpolarization-activated cy-
clic nucleotide–gated (HCN) channels (Hogan and
Poroli, 2008; Emery et al., 2011; Noh et al., 2014;
Young et al., 2014).
It has been known for 40 years that injury to sensory
axons can bring about changes in the organization of the
spinal cord sensory map (Devor and Wall, 1978), and
that sensory disturbances relating to neuropathic pain
can be attributed to changes in excitability of the
injured neuron and abnormal ongoing and evoked
discharge from ectopic neural pacemaker sites
(Govrin-Lippmann and Devor, 1978; Wall and Devor,
1983). These ideas were confirmed by showing that
ectopic discharge from the neuroma induced by nerve
injury or from dorsal root ganglia could be silenced by
lidocaine (Devor et al., 1992). The idea of central
sensitization was first put forward by Clifford Woolf in
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the early 1980s to describe the cascade of events that
are attributed to the maladaptive changes in plasticity
of sensory processing that occur in neuropathic pain
(Woolf, 1983; Woolf and Thompson, 1991; Woolf and
Mannion, 1999; Latremoliere and Woolf, 2009).
A. Excitation–Inhibition Balance in Neuropathic Pain
Following peripheral nerve injury or neuropathy,
central sensitization within the spinal cord results from
changes in synaptic transmission; excitatory synaptic
processes are enhanced, and inhibitory processes are
attenuated (Kuner, 2010; Prescott et al., 2014; West
et al., 2015). The intrinsic properties of dorsal horn
neurons such as rheobase, threshold, excitability,
and/or input resistance are little changed by peripheral
nerve injury (Balasubramanyan et al., 2006). This
finding is consistent with the likelihood that ongoing
ectopic activity in peripheral nerves is required to drive
and maintain central sensitization (Devor, 2006;
Pitcher and Henry, 2008; Gold and Gebhart, 2010;
Vaso et al., 2014; Daou et al., 2016; Sexton et al., 2017).
Numerous parallel and interdependent pathophysio-
logical processes in the periphery, spinal cord, and
higher centers contribute to the onset of neuropathic
pain. This very much complicates the search for effec-
tive therapeutic targets. Although gabapentinoids may
only bind to one specific target, the a2d-1 subunit of
voltage-gated Ca2+ channels (Gee et al., 1996; Field
et al., 2006; Offord and Isom, 2015), this interaction has
multiple consequences for synaptic transmission,
neuron-selective actions, and network excitability at
the spinal level (Biggs et al., 2014; Alles and Smith,
2016; Alles et al., 2017) and within higher brain centers
(Suzuki et al., 2005; Eroglu et al., 2009; Suto et al., 2014;
Crosby et al., 2015; Patel and Dickenson, 2016a;
Bannister et al., 2017b); this multiplicity of effect may
explain their therapeutic effectiveness. The apprecia-
tion of this concept has led to the evidence-based
development of drugs that will affect multiple targets
(Gadotti et al., 2015; Zamponi et al., 2015).
Details of pathophysiological processes that contrib-
ute to the development of neuropathic pain are outlined
in the following sections. In addition, and where
relevant, we identify experimental drugs that target
these changes. Some of these substances have not yet
been tested in the clinic, whereas others have yielded
TABLE 2
Examples of drugs in development that remain viable candidates for future therapeutic interventions
Drug Target Comments
Mg2+ NMDA receptors Some positive results reported in the clinic
(Pickering et al., 2011)
Cobazam a2 subunit of GABAA receptor Encouraging results in preliminary clinical
trials (Besson et al., 2015)
N-desmethyl clobazam a2 subunit of GABAA receptor Parent compound for development of new drugs
(Ralvenius et al., 2016)
m-TRTX-Hhn1b Nav1.7 Liu et al., 2014
m-SLPTX-Ssm6a Nav1.7 Yang et al., 2013
Monoclonal antibody Voltage sensor paddle domain of Nav1.7 Lee et al., 2014
ΟΒ21 STOML-3 and Piezo2 mechanoreceptor
channels
Wetzel et al., 2017
CLP-257 KCC2 (K+/Cl2 cotransporter) Gagnon et al., 2013
KYS05090S or ABT-639. . Small-molecule T-channel blockers Jarvis et al., 2014; Zhang et al., 2015a;
M’Dahoma et al., 2016
N-((1-(2-(tertbutylamino)-2-oxoethyl)piperidin-
4-yl)methyl)-9-pentyl-9Hcarbazole-3-
carboxamide
CB2 agonist that targets Cav3.2 T-type
channels
Berger et al., 2014; Bladen et al., 2015; Snutch
and Zamponi, 2017
A-1264087 State-dependent Cav2 blockers Oral administration of all of these drugs
displays antiallodynic efficacy in rodent
models (Patel et al., 2017)
TROX-1
ZC88.
Clobezam a2 subunit of GABAA (Besson et al., 2013) Encouraging results in
preliminary trials (Besson et al., 2015)
GCD-0276 Nav1.7 Under development (Bagal et al., 2014, 2015;
Yekkirala et al., 2017)GCD-0310
PF-05089771
BIIB074 Nav1.7 In phase 2a clinical trials (Zakrzewska et al.,
2017)
M4 Broad-spectrum dihydropyridine-related Ca2+
channel blocker blocks Cav 1.2 (L-type), Cav
2.2 (N-type), and Cav 3.2 and 3.3 (T-type
channels)
Under development (Gadotti et al., 2015;
Zamponi et al., 2015).
EMA401 AT2 (angiotensin) receptor antagonist Produces antinociception in mouse neuropathic
pain models and inhibits capsaicin-induced
calcium fluxes in human and DRGs
IB-MECA Adenosine A3 receptor Efficacy of A3 receptor agonists in relief of
allodynia in rodent models has been
convincingly demonstrated (Ford et al., 2015;
Little et al., 2015)
MRS5698
ICA-27243 KCNQ/Kv7.2/7.3 channel opener Effective in animal models of inflammatory
pain (Hayashi et al., 2014)
KCNQ, M-type potassium channel comprising Kv7.2 and Kv7.3 subunits.
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disappointing results in phase I or phase II trials.
Table 2 lists substances that remain as viable entities
for use as future therapeutic development.
B. The Colony-Stimulating Factor 1, Microglia,
Purinergic Ionotropic 2X4, ATP, Brain-Derived
Neurotrophic Factor, GABA-Chloride Cascade
1. Brain-Derived Neurotrophic Factor and a Shift in
Neuronal Chloride Gradient. Coull et al. (2003)
showed that a decrease in transmembrane chloride
gradient occurred in rat dorsal horn lamina I neurons
following peripheral nerve injury as a result of a
reduction in expression of the potassium-chloride ex-
porter, potassium-chloride exporter 2 (KCC2). The
resulting accumulation of intracellular Cl2 can cause
normally inhibitory GABAergic, anionic, outward syn-
aptic currents to become inward excitatory currents
(Coull et al., 2003; Prescott et al., 2006).
It was corroborated that this change was due to a
reduction in KCC2 expression as a knockdown of spinal
KCC2 in noninjured rats reduced pain thresholds and
resulted in neuropathic pain behaviors (Coull et al.,
2003, 2005). Hence, an injury that causes neuropathic
pain results in a marked change in dorsal horn function
such that the net excitability of nociceptive lamina I
neurons is increased. It was also shown more recently
that alterations in KCC2 expression in deep dorsal horn
neurons are confined to nociceptive neurons that project
via the spinothalamic tract, whereas wide dynamic
range neurons that are activated by a variety of sensory
modalities (Dalal et al., 1999) were unaffected (Lavertu
et al., 2014).
The Salter and de Koninck (Coull et al., 2005) groups
have also shown that brain-derived neurotrophic factor
(BDNF) release from activated spinal microglia is
responsible for the aforementioned depolarizing shift
in anion gradient observed in lamina I neurons in
neuropathic pain. In this study, administration of
activated microglia or application of BDNF produced
the shift in anion gradient seen after nerve injury. Also,
blocking signaling between BDNF and its cognate
receptor [tropomyosin receptor kinase B (TrkB)] re-
versed pain behaviors (allodynia) and the shift in anion
gradient. Lastly, allodynia and the shift in anion
gradient were shown to be prevented by blocking
release of BDNF from microglia by treatment with
interfering RNA against BDNF.
It was shown recently that BDNF potentiates excit-
atory NMDA receptor-mediated currents through acti-
vation of TrkB and phosphorylation of the GluN2B
subunit by the Src-family kinase Fyn (Hildebrand et al.,
2016). Interestingly, this potentiation appears to re-
quire the coincident BDNF-mediated Cl2 disinhibition.
The exact molecular mechanism of this interaction
remains to be elucidated as it does not appear to reflect
increased NMDA receptor availability as a result of
GABA-induced depolarization (Hildebrand et al., 2016).
2. Role of ATP. It is also known that, following
peripheral nerve injury, there is an increase in the
expression of the ATP-gated ionotropic purinoceptor,
2X4 (P2X4R), and in the metabotropic purinoceptor,
2Y12 (P2Y12R), in microglia. This increase in expres-
sion parallels the increase in pain hypersensitivity
(Tozaki-Saitoh et al., 2008; Trang et al., 2011, 2012).
The mechanism by which P2X4R upregulation leads to
BDNF release from microglia is attributed to influx of
Ca2+ through P2X4Rs, activation of p38 mitogen-
activated kinase, and a consequent increase in synthe-
sis and SNARE-mediated exocytosis of BDNF (Trang
et al., 2009). Interestingly, this mechanism is specific to
male mice as microglia are not required for mechanical
sensitivity to pain in female mice in which adaptive
immune cells are involved (Sorge et al., 2015; Sorge and
Totsch, 2017). Sex differences in pain processing are
currently a very active area of investigation with
obvious clinical implications (Mogil, 2012b; Mifflin and
Kerr, 2013; Dodds et al., 2016; Mifflin et al., 2017).
3. Signaling between Injured Peripheral Nerve and
Spinal Microglia. The transformation of resting
microglia into a phenotype that expresses P2X4R has
been ascribed to the release of chemical mediators from
injured primary afferent fibers. These include the
chemokines, fractalkine (Milligan et al., 2004; Grace
et al., 2014), chemokine (C-C motif) ligand (CCL)2, and
CCL21 (Biber et al., 2011; Toyomitsu et al., 2012).
Recent work, however, discounts these mediators and
instead favors colony-stimulating factor 1 (CSF-1) as
the primary effector of microglial transformation in
neuropathic pain (Guan et al., 2016; Okubo et al., 2016).
It has been suggested that the injury-induced release of
inflammatory mediators such as interleukin (IL)-1b
from satellite glial cells in DRG promotes induction of
Csf1 in the cell bodies of primary afferent neurons (Lim
et al., 2017). As will be discussed below, fractalkine and
CCL2 are involved in other aspects of the etiology of
neuropathic pain. CSF-1 is released from primary
afferents and acts on microglia to induce various
genes, including that for the ATP receptor, P2X4R,
as well as microglial proliferation and self-renewal
(Guan et al., 2016). The membrane adaptor protein
DAP12 is required for nerve injury–induced upregu-
lation of P2X4R, but not for microglial proliferation.
The relationship between CSF-1, P2X4R, ATP, and
BDNF is illustrated schematically in Fig. 2A. It
remains to be determined whether the release of
CSF-1 from primary afferents is vesicular and depends
on neuronal activity. This is important to know as it
may help to explain how injury-induced ectopic activity
in primary afferents leads to central sensitization.
BDNF is also released from sensory neurons in an
activity-dependent fashion (Balkowiec and Katz, 2000),
but it remains to be determined whether this process
contributes to the onset of neuropathic pain or whether
it is associated with more physiologic and reversible
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central sensitization as is seen in some types of in-
flammatory pain.
4. Source of ATP in Central Sensitization. After
peripheral nerve injury, increased spinal levels of ATP
reflect release from the dorsal horn neurons them-
selves and not from primary afferents, astrocytes, or
microglia. This increased release is brought about by
upregulation of the vesicular nucleoside transporter
(VNUT; Fig. 2, B and C) (Masuda et al., 2016).
Neurotransmitters are transported from the cyto-
plasm into synaptic vesicles via specific transporter
proteins: vesicular GABA transporter in inhibitory
neurons and various isoforms of the vesicular gluta-
mate transporter in excitatory neurons. Synaptic
vesicles in most, if not all, neurons contain ATP that
is released along with the primary neurotransmitter.
VNUT serves to transport cytosolic ATP into synaptic
vesicles. When it is upregulated after nerve injury,
vesicles contain a high level of ATP, which is released
and stimulates P2X4R on microglia. As mentioned
above, this promotes release of BDNF (Trang et al.,
2009). The mechanism whereby peripheral nerve in-
jury produces a trans-synaptic upregulation of VNUT
in dorsal horn neurons remains to be elucidated.
C. Increased Excitatory Drive to Excitatory Neurons
and Decreased Excitatory Drive to Inhibitory Neurons
Chronic constriction injury (CCI) or axotomy of the
sciatic nerve produces an electrophysiological footprint
of neuropathic pain in the substantia gelatinosa (Biggs
et al., 2010; Smith, 2014) (Fig. 3A). In this footprint,
neurons have been classified according to their firing
pattern as tonic, delay, irregular, phasic, or transient
(Balasubramanyan et al., 2006), and the effects of CCI
noted as increases or decreases in the amplitude and
frequency of spontaneous excitatory postsynaptic cur-
rent (sEPSC) or miniature excitatory postsynaptic
current (mEPSC). Given the established relationship
between neuronal firing pattern and its neurotransmit-
ter phenotype (Yasaka et al., 2010; Punnakkal et al.,
2014), the footprint reflects an increased excitatory
drive to putative excitatory delay-firing and transient-
firing neurons (Fig. 4A) and a decreased excitatory drive
to putative inhibitory tonic-firing neurons (Fig. 4B)
(Bailey and Ribeiro-da-Silva, 2006; Balasubramanyan
et al., 2006; Chen et al., 2009; Lu et al., 2009). Both of
these changes would be expected to produce an overall
increase in dorsal horn excitability. Decreased excitatory
drive to inhibitory neurons involves both pre- and post-
synaptic changes, including a decreased contribution of
Ca2+-permeable AMPA receptor to sEPSCs (Chen et al.,
2016). Increased excitatory drive to excitatory neurons
also involves presynaptic effects and a possible increased
contribution of Ca2+-permeable AMPA receptor to post-
synaptic events (Chen et al., 2013).
1. Role of Brain-Derived Neurotrophic Factor.
Treatment of substantia gelatinosa neurons in organo-
typic culture with BDNF for 5 to 6 days produces an
Fig. 2. (A) Diagram to illustrate some of the processes leading to central sensitization. Classic inflammatory mediators released at the site of injury
alter the properties of primary afferent fibers such that they become hyperexcitable and/or spontaneously active. CSF-1 released from primary
afferents changes the phenotype of microglia that they start to express new receptors, including purinergic ionotropic 2X4. ATP released from dorsal
horn neurons interacts with P2X4Rs on microglia to promote release of BDNF, which interacts with neurons to increase dorsal horn excitability. (B and C)
Diagrams to show how peripheral nerve injury increases ATP release from dorsal horn neurons by upregulating the vesicular nucleotide transporter VNUT.
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electrophysiological footprint (Lu et al., 2006; Biggs
et al., 2012) that is very similar to that produced by CCI
in vivo (Biggs et al., 2010; Smith, 2014). Both BDNF and
CCI increase sEPSC and mEPSC amplitude and fre-
quency in putative excitatory delay-firing neurons, and
amore detailed analysis shows that bothmanipulations
also unveil a new population of large mEPSC events,
which are absent in neurons from sham-operated rats
and control organotypic cultures (Biggs et al., 2010;
Smith, 2014). CCI-induced attenuation of excitatory
synaptic drive to inhibitory neurons is associated with
functional loss of Ca2+-permeable AMPA receptors in
the postsynaptic membrane (Chen et al., 2016). BDNF
has also been reported to activate presynaptic NMDA
receptors via a TrkB-dependent mechanism (Chen
et al., 2014). Somewhat counterintuitively, this has
been proposed to decrease neurotransmitter release
(Bardoni et al., 2004), which may contribute to attenu-
ation of synaptic events in inhibitory neurons of the
substantia gelatinosa.
Aswould be expected, spinal cord slices obtained from
animals subject to CCI and those in organotypic
cultures exposed to BDNF for 5 to 6 days displayed an
overall increase in excitability. This was observed as an
increase in the amplitude of Ca2+ responses evoked by
35 mM K+ (Lu et al., 2007; Alles et al., 2017). In
addition, activated microglia-conditioned medium in-
creased overall organotypic slice excitability, and pre-
incubation of slices with a TrkBd5 (recombinant
receptor, which sequesters BDNF) inhibited this effect
(Lu et al., 2009). This provides further evidence for the
role of microglia-derived BDNF as a major driver of
central sensitization (Coull et al., 2005; Biggs et al.,
2010; Trang et al., 2011; Smith, 2014).
2. Brain-Derived Neurotrophic Factor as a Drug
Target? Given the seminal role of BDNF in the onset of
neuropathic pain and findings that suggest its involve-
ment in pain maintenance (Wang et al., 2009), one may
posit that BDNF antagonists would be an effective
treatment (Sah et al., 2003). Because BDNF is involved
in so many other essential processes, such as neuronal
growth, survival, and synaptogenesis (Reichardt, 2006),
and in processes related to memory (Malcangio and
Lessmann, 2003; Montalbano et al., 2013), systemic
blockade of BDNF function in pain patients would
doubtless cause undesirable side effects, including
Fig. 3. (A) Diagram to illustrate the electrophysiological footprint of
neuropathic pain seen in substantia gelatinosa following peripheral nerve
injury (Biggs et al., 2010). Five cell types characterized by their firing pattern,
tonic, delay, irregular, phasic, or transient (Balasubramanyan et al., 2006), are
listed at the top of the scheme, and the frequencies and amplitudes of sEPSCs
and mEPSCs are listed at the right of the scheme. Upward arrows in green-
colored squares indicate a nerve injury–induced increase in each type of
synaptic event in each neuron type. Downward arrows in red-colored squares
indicate a nerve injury–induced decrease. nd = not determined; horizontal
double-headed arrow indicates no change. (B) Similar presentation to show
cell-type–specific effects of gabapentin in substantia gelatinosa of nerve-injured
animals. (C) Superimposition of patterns from (A) and (B). Yellow shading
represents phenomena that were affected in one way by nerve injury and the
opposite direction by gabapentin.
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cognitive impairment and the onset of depression
(Autry and Monteggia, 2012; Smith, 2014).
3. Use of Botulinum Toxin. Botulinum toxin repre-
sents another means by which to control neurotrans-
mitter release. Although it is currently a fourth-line
treatment (Finnerup et al., 2015), there is increasing
interest in its use in the management of neuropathic
pain (Oh and Chung, 2015; Baron and Binder, 2016;
Park and Park, 2017; Yaksh et al., 2017). Botulinum A
cleaves the synaptic protein SNAP-25 and thereby
decreases the Ca2+ responsiveness of the secretory
machinery and attenuation of neurotransmitter release
(Trudeau et al., 1998). Because the toxin blocks the
release of both inhibitory and excitatory transmitters,
its mechanism of action has been debated (Baron and
Binder, 2016). Actions may include attenuation of
neurogenic inflammation in the periphery. The sugges-
tion that the substantia gelatinosa is “primarily an
excitatory network” (Santos et al., 2007) in which only
25% of the neurons are inhibitory (Boyle et al., 2017)
may account for the actions of botulinum toxin at the
spinal level.
D. Altered Sensory Processing and Generation
of Allodynia
Following nerve injury, attenuation of GABAergic
and/or glycinergic transmission leads to aberrant pro-
cessing of sensory information within the dorsal horn
(Baba et al., 2003; Torsney and MacDermott, 2006;
Prescott et al., 2014). In addition to changes in chloride
gradient (Coull et al., 2003, 2005) and decreased excit-
atory drive to inhibitory neurons (Balasubramanyan
et al., 2006; Lu et al., 2009; Leitner et al., 2013), this
may involve a loss of GABAergic terminals (Lorenzo
et al., 2014) or reduced glycine release (Imlach et al.,
2016). Tactile and innocuous information is carried byAb
fibers, which synapse primarily onto dorsal horn neurons
in laminae III and IV (Abraira et al., 2017), whereas
noxious information carried by C and Ad fibers is trans-
mitted to the superficial laminae I and II (Peirs and Seal,
2016) (Fig. 1C). GABAergic and glycinergic inhibition
normally separates these two modalities by suppressing
the activity of pre-existing excitatory synaptic circuits
(Lu et al., 2013). However, when this inhibition is
compromised, tactile and innocuous information travel-
ing to lamina III and IV gains access to the pain-
processing centers in lamina I and II. Thus, touch is
processed as pain, thereby providing a rational explana-
tion for the generation of allodynia. This idea is sup-
ported by the observation that impediment of inhibitory
transmission in the spinal cord with bicuculline and/or
strychnine produces allodynia and hyperalgesia in un-
injured animals (Yaksh, 1989; Sherman and Loomis,
1994; Loomis et al., 2001).
Anomalous distribution of tactile information is
reinforced by increased excitatory transmission be-
tween deep and superficial laminae. This involves
transient expression of the vesicular glutamate trans-
porter vesicular glutamate transporter 3 by a discrete
population of neurons that receive direct low-threshold
primary afferent input (Fig. 1C). The circuit extends to
nociceptive lamina I projection neurons and includes
lamina II calretinin neurons (Peirs et al., 2015).
In addition to being a substrate for allodynia, injury-
induced ongoing aberrant activity in Ab fibers (Devor,
2009), including large-diameter cutaneous afferents
(Cummins et al., 2000), would be expected to drive
persistent activation of the superficial laminae that
may contribute to chronic, stimulus-independent pain.
1. Mechanosensitive Ion Channels as Therapeutic
Targets. Because light touch instigates allodynia,
there is interest in pharmacological manipulation of
normally innocuous modalities as a means to alleviate
Fig. 4. (A) Diagram to illustrate increase in excitatory synaptic trans-
mission onto excitatory dorsal horn neurons following CCI and reversal of
these changes following GBP treatment. The inset shows the character-
istic delay-firing pattern of excitatory neurons. Red arrows illustrate
relative quantity of glutamate released onto control excitatory neurons,
onto neurons in animals subject to CCI, and onto CCI neurons following
treatment with GBP. The inset shows the characteristic delay-firing
pattern of excitatory neurons. (B) Diagram to illustrate decrease in
excitatory synaptic transmission onto inhibitory dorsal horn neurons
following CCI and restoration of glutamate release following GBP
treatment. The inset shows the characteristic tonic-firing pattern of
inhibitory neurons. Red arrows illustrate relative quantity of glutamate
released onto control-inhibitory neurons, onto neurons in animals subject
to CCI, and onto CCI neurons following treatment with GBP.
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aspects of human neuropathic pain (Eijkelkamp et al.,
2013). Transduction of light touch by mechanoreceptors
is effected by the mechanosensitive ion channel, Piezo
2 (Ranade et al., 2014), which is modulated by stomatin-
like protein 3 (STOML-3) (Wetzel et al., 2007, 2017).
Interference with STOML-3 function has been proposed
as a novel therapeutic approach for neuropathic pain.
Recently, a small molecule blocker of STOML-3 oligo-
merization was identified. This substance termed OB-1
by the authors was shown to attenuate mechanorecep-
tor sensitivity and to increase paw withdrawal thresh-
old in mice subject to CCI (Wetzel et al., 2017).
2. Potentiation of GABA or Glycine as Therapeutic
Targets. Some of the anticonvulsant agents used in
pain management are thought to act, at least in part, by
augmentation of GABA function (Table 1). Given the
established role of GABAergic and glycinergic dysfunc-
tion in the etiology of allodynia (Yaksh, 1989; Sherman
and Loomis, 1994; Loomis et al., 2001), restoration of
this function represents an attractive therapeutic ap-
proach (Zeilhofer et al., 2012a, 2015). Augmentation of
glycinergic function may be achieved by pharmacolog-
ical manipulation of the glial and neuronal glycine
transporters GlyT1 and GlyT2 or direct stimulation of
glycine receptors (Zeilhofer et al., 2017).
The collapse of the chloride gradient in response to
CCI-induced release of BDNF from spinal microglia has
already been alluded to (Coull et al., 2003, 2005; Beggs
et al., 2004; Lavertu et al., 2014). Because this reflects
downregulation of the K+/Cl2 cotransporter KCC2,
there is considerable interest in developing pharmaco-
logical agents that will restore KCC2 function (Gagnon
et al., 2013). These authors identified an arylmethyli-
dine family of compounds and found that the analog
CLP257 was KCC2 selective and that it restored
impaired Cl2 transport and Cl2 gradients in neurons
with diminished KCC2 activity. It also alleviated
allodynia in a rat model of neuropathic pain with an
oral efficacy equivalent to PGB, thus validating KCC2
as a therapeutic target for neuropathic pain and
perhaps for other central nervous system (CNS) disor-
ders (Gagnon et al., 2013).
It is well established that GABAA receptor function is
augmented by benzodiazepines, but their use as anti-
allodynic agents in the clinic is limited by their sedative
effects (Besson et al., 2013). It is known, however, that
different subtypes of GABAA receptor localize with
different cell types and terminals in the spinal dorsal
horn. In particular, GABAA receptors containing the a2
subunit associate with C fibers (Paul et al., 2012), and
this has led to the notion that benzodiazepines with
high affinity for a2 may be effective in treating neuro-
pathic pain (Besson et al., 2013; Paul et al., 2014;
Ralvenius et al., 2016). One such agent, clobazam
(Besson et al., 2013), which acts through an active
metabolite (Ralvenius et al., 2016), is effective in re-
lieving allodynia in the CCI model (Besson et al., 2013).
Moreover, preliminary clinical trials with this agent are
showing encouraging results (Besson et al., 2015).
E. Other Spinal Mechanisms of Central Sensitization
1. Long-Term Potentiation and Memory Processes.
Transmission at CNS synapses is characteristically
plastic. Repeated activation of presynaptic fibers can
lead to short-term potentiation (lasting for less than
half an hour), early-phase long-term potentiation (LTP;
lasting for up to 3 hours), and late-phase LTP, which
depends on protein synthesis and can last indefinitely
(Luo et al., 2014). Given that peripheral nerve injury
increases activity of both primary afferent fibers and
dorsal horn neurons, these processes are doubtlessly
engaged and serve to reinforce central sensitization
(Ji et al., 2003; Sandkuhler, 2007; Fenselau et al., 2011;
Ruscheweyh et al., 2011; Luo et al., 2014). Mechanisti-
cally, spinal LTP involves presynaptic mechanisms
(Luo et al., 2014) as well as opening of T-type [voltagae-
gated Ca2+ channels type 3 (Cav3)] calcium channels and
activation of NMDA receptors (Ikeda et al., 2003, 2006;
Zhuo, 2016b). These receptors have long been implicated
in the etiology of neuropathic pain (Woolf andThompson,
1991; Kerr et al., 1999; Latremoliere and Woolf, 2009;
Salter and Pitcher, 2012; Hildebrand et al., 2016), and
this may account for the effectiveness of the NMDA
receptor blocker, ketamine, in the management of
chronic pain (Hewitt, 2000; Niesters et al., 2014; Maher
et al., 2017) and the observation that T-type calcium
channel blockers mibefradil and ethosuximide can re-
verse neuropathic pain in an animalmodel (Dogrul et al.,
2003). Physiological blockade of NMDA channels with
Mg2+ has been shown to be effective in reducing signs of
pain in animal models (Brill et al., 2002; Rondon et al.,
2010), and there is some evidence that it may play a role
in the treatment of human neuropathic pain (Pickering
et al., 2011).
Central sensitization in the dorsal horn shares many
mechanistic parallels with memory formation
(Sandkuhler and Lee, 2013), including reconsolidation,
a protein synthesis–dependent process by which mem-
ories become labile after reactivation and susceptible to
erasure (Nader et al., 2000; Debiec et al., 2002). Thus,
following lasting hyperalgesia induced by injection of
capsaicin or complete Freund’s adjuvant into mice
hindpaw, a second capsaicin injection administered
within 2 hours of the first suppressed hyperalgesia by
a mechanism independent of protein synthesis (Bonin
and de Koninck, 2014). It remains to be determined
whether this phenomenon can be exploited therapeuti-
cally in management of neuropathic pain.
2. Role of Astrocytic Glutamate Transporter (Excit-
atory Amino Acid Transporter 2). Studies using
various animal models have also reported that down-
regulation of the astrocytic excitatory amino acid
transporter, excitatory amino acid transporter 2
(EAAT2), correlates with development of signs of
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neuropathic pain (Cata et al., 2006; Weng et al., 2006).
Both partial sciatic nerve ligation and CCI significantly
reduce expression of EAAT2 in rat dorsal horn (Sung
et al., 2003), whereas spinal EAAT2 gene transfer via
recombinant adenovirus significantly decreases me-
chanical hyperalgesia and allodynia (Maeda et al.,
2008). Decreased removal of extracellular glutamate
following EAAT2 downregulation may lead to activa-
tion of extrasynaptic NMDA receptors (Nie and Weng,
2009). The signal responsible for EAAT2 downregula-
tion remains to be established. It is unlikely to be BDNF
as this neurotrophin upregulates EAAT2 in other brain
regions (Rodriguez-Kern et al., 2003).
Although riluzole, a positive regulator of glutamate
transporters, significantly reduces thermal hyperalge-
sia and mechanical allodynia in CCI (Sung et al., 2003),
this effect may reflect other actions of the drug such as
interaction with Na+ channels (Hebert et al., 1994;
Munro et al., 2007).
F. The Pain Matrix
Neuronal plasticity during neuropathic pain is by no
means limited to the dorsal horn and periphery (West
et al., 2015; Zhuo, 2016a,b; Bannister and Dickenson,
2017). Multiple changes are observed in the painmatrix
that includes the medial prefrontal cortex, nucleus
accumbens, anterior cingulate cortex, insula, amygdala,
periaqueductal gray, locus coeruleus, and rostroventral
medulla (Schweinhardt and Bushnell, 2010; von Hehn
et al., 2012; Zhang et al., 2015c; Peirs and Seal, 2016;
Tan et al., 2017; Taylor et al., 2017). For example,
synapses in the anterior cingulate cortex are altered
after peripheral nerve injury, and LTP of glutamatergic
transmission appears in the insula (Zhuo, 2016a). There
is also an increase in feed-forward GABAergic inhibi-
tion in the medial prefrontal cortex (Zhang et al., 2015c)
that is thought to contribute to the emotional aspects of
neuropathic pain.
Brain regions that comprise the pain matrix were
identified by functional neuroimaging (Apkarian et al.,
2011). Interestingly, areas activated by acute pain do
not correspond exactly to those activated in chronic pain
(Apkarian et al., 2011; von Hehn et al., 2012). The
“matrix is reloaded!”
G. Changes in Descending Control Mechanisms
In addition to altering pain perception, changes in the
pain matrix can also alter control of spinal dorsal horn
neurons as a result of alterations in descending control
mechanisms (Porreca et al., 2002; Ossipov et al., 2010).
The well-established role of serotonergic and noradren-
ergic pathways in controlling spinal nociceptive pro-
cessing (Ossipov et al., 2010) helps to explain the
effectiveness of tricyclic antidepressants and related
monoamine uptake inhibitors in pain management
(Dworkin et al., 2007; Kuner, 2010; Finnerup et al.,
2015; Bannister and Dickenson, 2017). Descending
inhibition of nociceptive processing is mediated via a2
adrenoceptors and 5HT7 receptors, whereas serotoner-
gic activation of metabotropic 5HT2 receptors and
ionotropic 5HT3 receptors facilitates transmission
(Millan, 2002; Bannister et al., 2015, 2017a; Bannister
and Dickenson, 2017).
Although intrathecal administration of the a2 re-
ceptor antagonist, yohimbine, hastens the onset of cold
allodynia and heat sensitivity following tibial nerve
transduction, the drug loses its sensitizing effect once
these phenomena have fully developed. These findings
have been interpreted as a loss of descending noradren-
ergic control once allodynia and hyperalgesia have
developed (Hughes et al., 2013). Similarly, silencing of
locus coeruleus neurons by adenoviral infection of K+
channels attenuates descending inhibition, but this
effect disappears once neuropathy is introduced
(Howorth et al., 2009).
Experiments with the antagonist, ondansetron, im-
plicate upregulation of 5HT3 receptor function in the
generation of neuropathic pain (Bannister et al., 2015).
The resulting facilitation of nociceptive processing
along with attenuation of the inhibitory actions of
noradrenaline thus conspires to promote allodynia and
hyperalgesia.
For additional information on mechanisms of central
sensitization and allodynia, consult publications by
Jürgen Sandkühler (Sandkuhler, 2009; Ruscheweyh
et al., 2011; Sandkuhler and Gruber-Schoffnegger,
2012), Clifford Woolf (Ji and Woolf, 2001; Costigan
et al., 2009b; Latremoliere and Woolf, 2009), and Allan
Basbaum (Basbaum et al., 2009), as well as that by
Peirs and Seal (2016). Several additional reviews
address supraspinal changes associated with neuro-
pathic pain (Zhuo, 2008, 2016b; Luo et al., 2014)
and alterations in descending control mechanisms
(Bannister and Dickenson, 2017).
H. Role of Mesolimbic Reward Circuitry
An emerging area in the study of neuropathic pain
mechanisms relates to the ability of peripheral nerve
injury to impair dopamine release in the reward
circuitry associated with mesolimbic system (Taylor
et al., 2015, 2017). This may relate to the changes in
affect (anxiety, depression) experienced by neuropathic
pain patients (Mitsi and Zachariou, 2016). It was also
shown recently that peripheral nerve injury selectively
increases excitability of the nucleus accumbens indirect
pathway spiny projection neurons and alters their
synaptic connectivity. In addition, tactile allodynia
was reversed by inhibiting and exacerbated by exciting
these neurons. This suggests that neurons in the
nucleus accumbens not only participate in the central
representation of pain, but that they may gate activity
in ascending pathways associated with expression of
neuropathic pain in higher centers (Ren et al., 2016).
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I. Role of Ectopic Activity in Primary Afferent Fibers
The initial inflammatory event at the site of nerve
injury is a major trigger for the sequelae that lead to
central sensitization (Watkins and Maier, 2002; Scholz
and Woolf, 2007; White et al., 2007; Basbaum et al.,
2009; Stemkowski and Smith, 2012b; Grace et al., 2014;
Schuh et al., 2014; Ko et al., 2016) (Fig. 2A). As
mentioned above, processes involved in the onset of
neuropathic pain are very different from those involved
in its long-term persistence and maintenance (Ji and
Woolf, 2001). Classic mediators of inflammation such as
IL-1b (Binshtok et al., 2008; Stemkowski and Smith,
2012a,b; Stemkowski et al., 2015), IL-6 (Ko et al., 2016),
prostaglandins (Ma and Eisenach, 2002), and tumor
necrosis factor (TNF) (Leung and Cahill, 2010) interact
with or modulate ion channels on primary afferent
neurons to instigate ectopic activity that contributes
to spontaneous, stimulus-independent pain (Pitcher
and Henry, 2008; Devor, 2009; Devor et al., 2014).
Indeed, it has been shown that, following a peripheral
nerve injury, there is altered synaptic activity of sub-
stantia gelatinosa neurons with little effect on their
intrinsic electrophysiological properties, suggesting
that changes in the CNS are driven by activity of
peripheral neurons (Balasubramanyan et al., 2006;
Devor, 2006). In a simple yet elegant series of experi-
ments, it was shown by application of lidocaine to block
nerve conduction and subsequent monitoring of spon-
taneous baseline discharge that the hyperexcited state
of dorsal horn neurons is maintained by ongoing,
afferent discharges from the peripheral nerve distal to
and proximal to the site of injury (Pitcher and Henry,
2008). Increased activity in afferent nerves leads to
upregulation of the a2d-1 subunit of voltage-gated Ca2+
channels (Boroujerdi et al., 2008). This in turn alters
Ca2+ channel function in primary afferent terminals
and increases transmitter release (see Gabapentinoids
and the a2d Subunits of Voltage-Gated Ca2+ Channels).
Increased discharge in TRPV1-expressing neurons
may contribute to central sensitization more indirectly
by increasing the permeability of the blood brain and
blood spinal cord barrier (Beggs et al., 2010). This
permits access of proinflammatory cytokines and im-
munocompetent cells such as T-lymphocytes and mac-
rophages (Calvo et al., 2012).
1. Changes in Voltage-Gated Na+ Channels. As
mentioned, increases in various types of voltage-gated
sodium channel current contribute to the increased
excitability of DRG neurons seen in neuropathic pain
(Cummins andWaxman, 1997; Waxman et al., 2000a,b;
Abdulla and Smith, 2001a, 2002; Stemkowski and
Smith, 2012b; Bourinet et al., 2014; Waxman and
Zamponi, 2014). Genetic studies have confirmed the
importance of voltage-gated sodium channels by show-
ing that gain-of-function mutations in Nav1.7, Nav1.8,
and Nav1.9 are implicated in peripheral neuropathy
disorders in humans by increasing the excitability of
nociceptive neurons (Dib-Hajj et al., 2013; Sexton et al.,
2017; Yekkirala et al., 2017).
a. Peripheral Na+ channels as drug targets.
Pharmacological treatments such as carbamazepine,
which are known to target Na+ channels, have been
used for many years to treat some types of neuropathic
pain (Demant et al., 2014), particularly trigeminal
neuralgia (Walsh and Smith, 1968). Several small-
molecule blockers with affinity for Nav1.7, 1.8, or 1.9
have been considered. To date, the most promising
compounds that are currently in phase 1 or phase
2 clinical trials target Nav1.7 [Table 2; for additional
information, see review by Yekkirala et al. (2017)].
Small-molecule peptide blockers of Nav1.7 (for exam-
ple, m-TRTX-Hhn1b derived from spider venom or
m-SLPTX-Ssm6a from centipede venom) are also of
interest (Yang et al., 2013; Liu et al., 2014). A monoclo-
nal antibody targeting the voltage sensor paddle do-
main of Nav1.7 is available to allow for greater sodium
channel subtype selectivity (Lee et al., 2014). Slow
inactivation-specific channel modulators represent an-
other method by which ion channels can be stabilized in
their slow inactivated state to act as a brake during
periods of neuronal hyperexcitability, and these have
been applied to target both sodium and calcium channel
currents for treatment of neuropathic pain (Hildebrand
et al., 2011).
A recent review drew attention to the possible
pharmacological manipulation of b subunits of Na+
channels rather than the pore-forming a subunits
(O’Malley and Isom, 2015). This approach may be
especially attractive as three different types of b
subunits are differentially and selectively expressed in
small, medium, and large DRG neurons (Zhao et al.,
2011; Ho et al., 2012).
Further to its obvious role in controlling neuronal
excitability, the importance of Nav1.7 in normal and
pathologic pain processing may derive from its ability to
directly or indirectly affect several other processes,
including gene expression (Sexton et al., 2017). These
authors have brought forward the possibility that
upregulation of the penk (preproenkephalin) gene may
contribute to the beneficial effects of Nav1.7 blockers.
This is supported by the observation that the analgesic
effect of a selective Nav1.7 blocker, mu-theraphotoxin-
Pn3a (from the tarantula Pamphobeteus nigricolor), is
augmented by administration with subeffective doses of
opioids or with an enkephalinase inhibitor (Deuis et al.,
2017).
In a more straightforward physiologic mechanism,
Nav1.7 appears to be necessary for substance P release
from primary afferent terminals (Minett et al., 2012).
2. Changes in High Voltage–Activated Ca2+ Channels
(Cav1 and Cav2). Voltage-gated calcium channels are
another player in the field of neuropathic pain and pain
therapeutics in general (Baccei and Kocsis, 2000;
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Abdulla and Smith, 2001b; Bourinet et al., 2014;
Waxman and Zamponi, 2014; Zamponi et al., 2015;
Pan et al., 2016; Zamponi, 2016; Patel et al., 2017).
These channels encompass high-voltage–activated
(HVA) L-types (Cav1.1, Cav1.2, Cav1.3, and Cav1.4):
P/Q-type (Cav2.1), N-type (Cav2.2), and R-type (Cav2.3),
as well as T-type [low-voltage–activated (LVA)] Ca2+
channels (Cav3.1, Cav3.2, Cav3.3) (Zamponi et al., 2015;
Dolphin, 2016). Influx of Ca2+ through HVA-Ca2+
channels triggers neurotransmitter release from pre-
synaptic vesicles and thereby determines neuronal
network excitability. The importance of HVA-Ca2+
channels in neuropathic pain is illustrated by the
clinical effectiveness of the N-type Ca2+ channel blocker
ziconotide (Zamponi, 2016) and, as will be discussed
below, the relationship between HVA-Ca2+ channel
function a2d-1 subunits and the actions of gabapenti-
noids (Dolphin, 2012b). (See Gabapentinoids and the
a2d Subunits of Voltage-Gated Ca2+ Channels and a2d
Subunits and Neuropathic Pain.)
Voltage-gated Ca2+ channels (VGCC) consist of five
subunits, as follows: the a1 pore-forming subunit and
auxiliary subunits a2-d, b, and g. The main subtype
found in presynaptic terminals is Cav2 (Westenbroek
et al., 1998; Zamponi et al., 2015). Cav2.1 and Cav2.2
both contain a synaptic protein interaction site (syn-
print) that interacts with SNARE proteins (syntaxin
and SNAP-25) (Rettig et al., 1996; Sheng et al., 1996).
By this mechanism, channels can be closely associ-
ated with synaptic vesicles that govern release of
neurotransmitter.
Because these channels are responsible for
depolarization-induced influx of Ca2+ and triggering
consequent release of neurotransmitter, blocking or
genetically deleting these channels in hyperexcitable
nociceptive neurons would be expected to reduce net
excitability (Bourinet et al., 2014). For example, N-type
VGCC knockout mice exhibit reduced signs of both
inflammatory and neuropathic pain (Saegusa et al.,
2001).
It is important to note, however, that there is a classic
third–fourth power relationship between Ca2+ influx
and neurotransmitter release (Dodge and Rahamimoff,
1967). In other words, even if one were to reduce the
amount of Ca2+ entering terminals via VGCCs, there
would still be sufficient VGCCs expressed to support
substantial neurotransmitter release. This is supported
by experiments showing that 200 mM Mn2+, a pan-
VGCC blocker, produces no change in sEPSC frequency
or amplitude of spinal dorsal horn neurons, but can
produce a significant reduction of the amplitude of
35 mMK+-evoked Ca2+ responses that reflect activation
of voltage-gated Ca2+ channels following the depolariz-
ing action of a high concentration of extracellular K+
(Biggs et al., 2014).
If suppression of Ca2+ entry via presynaptic Cav2
channels has only verymodest effects onneurotransmitter
release from primary afferents, these observations raise
the question of how conotoxin channel blockers actually
work. It has, however, long been known that v-conotoxin
GVIA reduces synaptic potentials in the spinal cord (Yu
et al., 1992). In the clinical setting, it is also possible that
Cav2 channel block may have additional long-term conse-
quences, including effects on gene expression, as has been
suggested for Nav1.7 channels (Deuis et al., 2017; Sexton
et al., 2017). Effects of Cav2 block may be mediated via
long-term changes in intracellular Ca2+ handling by
mitochondria (D’Arco et al., 2015). It is also known that
nerve injury downregulatesHVA calcium channel current
(ICa) in DRG neurons (Baccei and Kocsis, 2000; Hogan
et al., 2000; Abdulla and Smith, 2001b; Pan et al., 2016). If
a similar or greater decrease occurs in primary afferent
terminals, this downregulation in combination with chan-
nel block may be sufficient to attenuate neurotransmitter
release in the dorsal horn.
a. Cav2 channels as therapeutic targets. In view of
the inconvenient pharmacokinetics of peptide neuro-
toxins such as ziconotide (synthetic v-conotoxin
MVIIA), which has to be administered intrathecally
(McGivern, 2007), there is considerable interest in
developing small-molecule blockers of CaV2 channels
(Waxman and Zamponi, 2014; Zamponi et al., 2015;
Zamponi, 2016; Patel et al., 2017). Several state-
dependent Cav2 blockers are currently under develop-
ment, including ZC88 (Meng et al., 2008; Zhang et al.,
2015b), A-1264087 (Xu et al., 2014; Zhu et al., 2014), and
TROX-1 (Abbadie et al., 2010; Swensen et al., 2012;
Patel et al., 2015). Oral administration of all of these
drugs displays antiallodynic efficacy in rodent models of
neuropathic pain (Patel et al., 2017).
N-type Ca2+ channels are also modulated by a2-
adrenoceptor agonists such as clonidine (Abdulla and
Smith, 1997) and opioids (Seward andHenderson, 1990;
Abdulla and Smith, 1998; Altier and Zamponi, 2008).
Given their limited clinical efficacy and loss of func-
tionalm-opioid receptors after nerve injury (Abdulla and
Smith, 1998; Zhang et al., 1998), actions of opioids are
not particularly relevant to discussion of neuropathic
pain. In contrast, the a2 adrenoceptor agonist, cloni-
dine, displays antiallodynic actions in a rodent model
(Puke et al., 1991), and meta-analysis of clinical trials
suggests some clinical efficacy (Giovannitti et al., 2015).
These effects may be mediated by restoration of a2
adrenergic modulation of pain processing at the spinal
level following peripheral nerve injury (Bannister and
Dickenson, 2017) and/or by attenuation of aberrant
interactions between sympathetic and sensory nerves
in the periphery (McLachlan et al., 1993; Abdulla and
Smith, 1997; Yen et al., 2006). N-type Ca2+ channels in
DRG are also modulated by neuropeptide Y (NPY), and
this effect, which is mediated via Y2 receptor, is in-
creased after nerve injury (Abdulla and Smith, 1999).
This has led to the suggestion that Y2 agonists, which
suppress excitatory synaptic transmission in substantia
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gelatinosa, may play a role in the management of
neuropathic pain (Moran et al., 2004; Smith et al.,
2007). This idea is supported by the observation that
intrathecal injection of NPY attenuates mechanical and
cold hypersensitivity in the rodent (spared nerve injury)
model (Intondi et al., 2008). Spinal galanin receptors
may represent an additional drug target (Alier et al.,
2008). Both NPY and galanin are found in inhibitory
interneurons in dorsal horn (Iwagaki et al., 2013; Boyle
et al., 2017; Todd, 2017).
b. Cav1 channels as therapeutic targets. In addition
to the established role of changes in N-type Ca2+
channels, certain lines of evidence support an addi-
tional contribution of L-type Ca2+ channels in the
maintenance of neuropathic pain (Balasubramanyan
and Smith, 2005; Fossat et al., 2010; Chang et al., 2015;
Radwani et al., 2016). This has led to increased interest
in broad-spectrum dihydropyridine-related Ca2+ chan-
nel blockers such as M4, which blocks Cav 1.2 (L-type),
Cav 2.2 (N-type), and Cav 3.2 and 3.3 (T-type channels)
(Gadotti et al., 2015; Zamponi et al., 2015). Possible
cardiovascular actions of this type of substance may
curtail their further therapeutic development,
3. Changes in LVA Ca2+ Channels (Cav3). By
contrast with the role of P/Q-type (Cav2.1) and N-type
(Cav2.2), HVA-Ca
2+ channels in neurotransmitter re-
lease, T-type, LVA, Ca2+ channels (Cav3.1, Cav3.2,
Cav3.3) play an important role in setting neuronal
excitability. In view of this, there is considerable in-
terest in targeting these channels in pain management
(Altier and Zamponi, 2004; Iftinca and Zamponi, 2009;
Todorovic and Jevtovic-Todorovic, 2013; Snutch and
Zamponi, 2017). This is especially the case as T-type
Ca2+ channel currents are increased in sensory neu-
rons following nerve injury in a model of diabetic
neuropathy (Jagodic et al., 2007, 2008). Mechanisti-
cally, this may involve upregulation of the deubiquiti-
nase, USP5, by the action of the inflammatory
mediator IL-1b. The resultant impairment of Cav3.2
channel ubiquitination would prolong surface expres-
sion of T-type LVA Ca2+ channels and thereby promote
increased excitability (Stemkowski et al., 2017).
a. Cav3 channels as therapeutic targets. The obser-
vation that T-type Ca2+ channel blockersmibefradil and
ethosuximide acutely increase withdrawal thresholds
in rats subject to nerve injury further supports the
suggestion that T-type channels are involved in neuro-
pathic pain expression. Small-molecule T-channel
blockers (KYS05090S or ABT-639) also showed promise
in preclinical studies (Jarvis et al., 2014; Zhang et al.,
2015a; M’Dahoma et al., 2016). Unfortunately, pre-
liminary clinical results with ABT-639 have been
disappointing (Patel et al., 2015).
Cannabinoids, which are effective in some neuro-
pathic pain cases (Moulin et al., 2014; Hauser et al.,
2017), inhibit recombinant human T-type (Cav 3.1, 3.2)
Ca2+ channels (Ross et al., 2008), and intrathecal
injection of the cannabinoid receptor 1/cannabinoid
receptor 2 (CB2) receptor agonist NMP-7 inhibits
injury-induced neuropathic pain in a rodent model.
This effect involves CB2 receptors and Cav3.2 channels
(Berger et al., 2014). To the best of our knowledge, NMP-
7 has not yet progressed to clinical trials, but its
preclinical effectiveness led to the development of the
derivative [N-((1-(2-(tertbutylamino)-2-oxoethyl)-
piperidin-4-yl)methyl)-9-pentyl-9Hcarbazole-3-carboxamide],
which displays remarkable effectiveness in both inflamma-
tory and neuropathic pain (Bladen et al., 2015).
Several additional small molecules that modulate
Cav3.2 channels either directly or via CB2 receptor
activation are in early preclinical development. For
further information, see review by Snutch and Zamponi
(2017).
4. Changes in Hyperpolarization-Activated Cyclic
Nucleotide–Gated Channels. HCN channels have
emerged as a promising peripheral drug target for
neuropathic as well as inflammatory pain (Chaplan
et al., 2003; Emery et al., 2011, 2012; Noh et al., 2014;
Young et al., 2014; Tsantoulas et al., 2016). HCN2 is
expressed in about half of small somatosensory neu-
rons, which are mainly nociceptors, and plays an
important role in the control of firing frequency in
response to noxious stimuli (Emery et al., 2011). Indeed,
deletion of HCN2 in nociceptive neurons prevents the
development of inflammatory and neuropathic pain
(Emery et al., 2011).
HCN channels are upregulated after nerve injury,
and it is thought that they drive spontaneous activity in
the DRG (Luo et al., 2007; Emery et al., 2011, 2012;
Young et al., 2014) to increase transmitter release from
primary afferents (Antal et al., 2004; Papp et al., 2006).
a. HCN channels as therapeutic targets. Ablocker of
HCN channels, ivabradine, which is also used clinically
to treat angina and heart failure, has been shown to be
effective in treating signs of neuropathic pain in animal
models through peripheral action on small sensory
neurons and to decrease firing frequency in cultured
DRG neurons from nerve-injured animals (Noh et al.,
2014; Young et al., 2014). More recent work has focused
on the search for selective HCN2 blockers (Sartiani
et al., 2017) that may abrogate hyperexcitability of
DRG neurons without affecting the HCN1 channels
that are responsible for controlling cardiac rhythmicity
(Tsantoulas et al., 2016).
5. Changes in K+ Channels. Attenuation of various
types of K+ channel conductance also contributes to the
increased excitability of DRG neurons that follows injury
or exposure to inflammatory cytokines such as IL-1b
(Abdulla and Smith, 2001a,b; Kim et al., 2002; Tan et al.,
2006; Stemkowski et al., 2015; Cao et al., 2012;
Stemkowski and Smith, 2012a; Tsantoulas et al., 2012;
Waxman and Zamponi, 2014; Gonzalez et al., 2017).
Changes in K+ channel currents may also contribute to
pain associatedwith diabetic neuropathy (Cao et al., 2010).
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This prompted the suggestion that the anticonvulsant
retigabine (Passmore et al., 2003) and related Kv7.2–Kv7.3
channel openers (Zhang et al., 2013; Busserolles et al.,
2016), as well as facilitators of Na+ activated K+ channel
currents (Huang et al., 2013) or two pore K+ channels or
KV2 orKv9.1 channels,may beuseful in painmanagement
(Tsantoulas et al., 2012; Yekkirala et al., 2017). Unfortu-
nately, a clinical trial with retigabine failed to meet its
primary efficacy end point (Yekkirala et al., 2017). The
retigabine analog N-(6-chloro-pyridin-3-yl)-3,4-difluoro-
benzamide (ICA-27243) has been reported to attenuate
inflammatorypain inanimalmodels (Hayashi et al., 2014),
but we are unaware of any clinical trials with this
substance. Beyond neuropathic pain arising from periph-
eral nerve injury, it has been reported that injury to the
spinal cord per se can impede K+ channel function in DRG
(Ritter et al., 2015), and this may contribute tomechanical
allodynia. Altered K+ channel function in DRGmay reflect
the diffusion of inflammatory mediators from the site of
injury within the spinal cord (Carlton et al., 2009).
Changes in K+ channel function may not always
involve changes in expression or properties of pore-
forming a subunits themselves but may rather result
from changes in regulatory subunits. For example, it
was recently shown that K+ channel modulatory sub-
units KChIP1, KChIP2, and DPP10 are coexpressed
with Kv4.3 in nonpeptidergic small neurons of the rat
DRG. Spinal nerve ligation downregulated all three
modulatory subunits, and their knockdown by intra-
thecal injection of a gene-specific antisense oligodeox-
ynucleotides evoked mechanical hypersensitivity.
Rescue of the downregulated subunits by injection of
appropriate cDNA constructs attenuated injury-
induced hypersensitivity (Kuo et al., 2017). These
findings imply that targeting of regulatory subunits
rather than pore-forming subunits of K+ channels may
lead the way to new therapeutic approaches. This is in
fact analogous to targeting the a2d-1 subunit of Ca2+
channels by gabapentin to control a subunit function
(Dolphin, 2016) and to the suggested targeting of non-
conducting b subunits of Na+ channels (O’Malley and
Isom, 2015).
6. Changes in Transient Receptor Potential Channels.
TRPV1 are nonselective cation channels that belong to
the larger group of multifunctional TRP channels
(Nilius et al., 2007). They are activated by the vanilloid,
capsaicin, and by noxious heat, low pH, osmolarity
changes, and arachidonic acid metabolites (Caterina
and Julius, 2001). TRPV1 sensitivity to temperature is
increased following exposure to nociceptive molecules
like nerve growth factor, or agents acting through G
protein–coupled receptors such as bradykinin, prosta-
glandin E2, or angiotensin acting on angiotensin type
2 receptors (AT2) (Yekkirala et al., 2017).
A recent paper addresses the role of the cold-sensing
channel, TRP channel type M8 (TRPM8), in cold
allodynia (Gonzalez et al., 2017). Nerve injury does
not appear to directly upregulate this channel but
rather decreases expression of an excitability brake
potassium current (Kv1.1–1.2) in cold-sensitive DRG
neurons. Cold-induced currents through an unchanged
population of TRPM8 are thus more effective in pro-
moting depolarization and increased action potential
discharge.
a. Transient receptor potential type V1 channels as
therapeutic targets—capsaicin and transient receptor
potential channel type V1 antagonists. TRPV1 is
upregulated in DRG following partial nerve injury or
spinal nerve ligation (Hudson et al., 2001; Fukuoka
et al., 2002), and TRPV1 antagonists have been shown
to attenuate injury-induced hyperalgesia (Basso and
Altier, 2017). These findings implicate TRPV1 channels
in the etiology of neuropathic pain, and it is possible
that other TRP channels such as TRPM8 and TRP
channel type A1 also play a role (Basso and Altier,
2017). Because TRPV1 antagonists are effective in
animal models, it seems paradoxical that capsaicin
patches are somewhat effective in management of
neuropathic pain (Finnerup et al., 2015). One explana-
tion may be that the Ca2+ influx induced by TRPV1
activation destroys nociceptor terminals or that the
receptors become desensitized and no longer respond to
inflammatory mediators. Given the demonstration of
interruption of pain memory in animal models by
capsaicin (Bonin and de Koninck, 2014), perhaps some
of its actions in the clinic reflect the presence of a
reconsolidation phenomenon in human neuropathic
pain.
b. Transient receptor potential type V1 channels as
therapeutic targets—angiotensin receptor type 2 receptor
antagonists. The observation that activation of the
AT2 can enhance TRPV1 channel function has brought
forward the idea that it may serve as a therapeutic
target in control of neuropathic pain (Smith et al., 2013;
Ink and Schatman, 2017; Yekkirala et al., 2017). The
AT2 receptor antagonist EMA401 produces dose-
dependent antinociception in mouse neuropathic pain
models and inhibits capsaicin-induced calcium fluxes in
human and DRGs (Anand et al., 2013). The results of
phase I and II clinical trials in patients suffering from
postherpetic neuralgia are encouraging as EMA401
produces significant analgesia (Rice et al., 2014; Rice
and Smith, 2015). The tolerability of EMA401 may
reflect the fact that cardiovascular, renal, and vasocon-
strictor actions of angiotensin are mediated by the
angiotensin receptor type 1.
J. Neuroimmune Interactions in Neuropathic Pain
In addition to the obvious importance of neurons and
the accepted role of microglia in the initiation of
neuropathic pain (Coull et al., 2005; Lu et al., 2009;
Beggs and Salter, 2012b, 2013), the role of other
immunocompetent cells, such as astrocytes, endothelial
cells, perivascularmacrophages, infiltrating T cells, and
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satellite glial cells of DRG neurons, must not be
overlooked (DeLeo et al., 2007; Scholz and Woolf,
2007; Costigan et al., 2009a; Beggs et al., 2010; Calvo
et al., 2012; Grace et al., 2014; Vicuna et al., 2015;
Dodds et al., 2016; Ji et al., 2016; Lim et al., 2017;
Mikuzuki et al., 2017). This follows the recognition
that immune cells express many of the receptors and
transduction mechanisms that are activated by injury
to neurons (Chiu et al., 2012). The idea of immune
system involvement in chronic pain came about from
observing classic signs of a systemic sickness response
(malaise, lethargy, depression, anxiety) in chronic pain
patients. This idea was later corroborated by findings
showing that elevated levels of IL-1b in peripheral
nerves could both mediate and induce hyperalgesia
(Grace et al., 2014). It was also demonstrated that
IL-1b, in addition to its proinflammatory actions, can
directly activate nociceptors to generate action poten-
tial firing, increased membrane availability of Cav3.2
(T-type) channels (Stemkowski et al., 2017), and
hyperalgesia (Binshtok et al., 2008; Stemkowski and
Smith, 2012a; Stemkowski et al., 2015). As already
mentioned, cytokines such as IL-1bmay be responsible
for increased expression of CSF-1 in primary afferent
neurons (Lim et al., 2017). This in turn is released into
the spinal cord, where it promotes BDNF release from
microglia and increased dorsal horn excitability (Guan
et al., 2016; Okubo et al., 2016) (Fig. 2A).
In addition to altering neuronal activity via the
release of BDNF, reactive microglia release cytokines
and chemokines such as fractalkine and other inflam-
matory mediators that trigger peripheral immune cell
infiltration and astrogliosis. In addition, damaged
sensory neurons release CCL2 (also known as monocyte
chemoattractant protein 1) as well as neuregulin 1 and
fractalkine. The net effect of complex interactions be-
tween invading and resident immunocompetent cells
and numerous signaling molecules is the generation of
classic inflammatorymediators such as IL-1b, IL-6, and
IL-18, and TNF. These influence neuronal activity by
facilitation of spinal LTP (Gruber-Schoffnegger
et al., 2013), direct excitatory actions on neurons
(Binshtok et al., 2008; Gustafson-Vickers et al., 2008;
Kawasaki et al., 2008; Stemkowski and Smith,
2012a; Stemkowski et al., 2015), increased release
of glutamate from primary afferents (Yan and Weng,
2013), and decreased release of GABA from dorsal
horn interneurons (Zhang and Dougherty, 2011).
It is noteworthy that generation of mediators such as
IL-1b and TNF may not be entirely maladaptive as
cytokines have been implicated in functional recovery of
damaged nerves (Nadeau et al., 2011) and neuroin-
flammation may assist in remyelination (Goldstein
et al., 2016).
A further development in the area of neuroimmune
interactions related to pain is the observation that
bacterial infections can cause pain via pathogens
interacting directly with and activating nociceptors
(Chiu et al., 2013; Ji et al., 2016).
A full description of neuroimmune interactions in
neuropathic pain is beyond the scope of the present
review. For further information, the reader is referred
to reviews by Linda Watkins and others (DeLeo et al.,
2007; Milligan and Watkins, 2009; Grace et al., 2014;
Dodds et al., 2016; Mifflin and Kerr, 2017). Although
targeting the immune systemmay seem a rational basis
for developing antiallodynic drugs (Leung and Cahill,
2010), to the best of our knowledge, no suitable small
molecules have yet been identified (Yekkirala et al.,
2017). This lack of success may be attributed, at least in
part, to the notion that neuroimmune interactions
trigger the onset of neuropathic pain, whereas other
mechanisms, more relevant to the clinical presentation,
are responsible for its long-term maintenance.
K. Adenosine A3 Receptors as a Therapeutic Target
The idea that themost effective agents in neuropathic
pain management likely exert actions through multiple
targets has already been alluded to. Adenosine A3
receptor agonists represent one such class of agents as
they interact with several of the pathophysiological
mechanisms outlined above (Janes et al., 2016). A3
receptors are found on immune cells, astrocytes (Bjor-
klund et al., 2008; Janes et al., 2015), microglia
(Hammarberg et al., 2003), and both peripheral and
central neurons (Janes et al., 2016). In addition, the A3
receptor agonist MRS5698 attenuates KCC2 downre-
gulation and restores Cl2 gradients in rodent CCI
models (Ford et al., 2015), a process that may involve
attenuation of BDNF signaling (Janes et al., 2016). A3
receptor activation also attenuates neuroinflammatory
responses, astrocyte reactivity, and cytokine release
(Janes et al., 2015, 2016). Efficacy of A3 receptor
agonists such as IB-MECA and MRS5698 in relief of
allodynia in rodentmodels of neuropathic pain has been
convincingly demonstrated (Ford et al., 2015; Little
et al., 2015). Because cardiovascular actions of adeno-
sine are mediated via A1 and A2 adrenoceptors
(Sawynok, 2016), A3 agonists show considerable prom-
ise as therapeutic agents (Janes et al., 2016). The
results of clinical trials are thus eagerly awaited.
III. Current Therapeutic Management of
Neuropathic Pain: Focus on Gabapentinoids
Whereas opioids are highly effective in many forms of
nociceptive pain (Yekkirala et al., 2017), an equivalent
panacea for the management of neuropathic pain is yet
to appear (Patel et al., 2017). As mentioned above, loss
of opioid effectiveness after nerve injury may reflect
downregulation or attenuated signaling via m opioid
receptors (Abdulla and Smith, 1998; Zhang et al., 1998;
Kohno et al., 2005). This underlines the urgent need to
develop new drugs. Despite the extensive investigation
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of signaling mechanisms associated with neuro-
pathic pain and the new data available, with the
possible exception of cannabinoids (Hauser et al.,
2017; Yekkirala et al., 2017), essentially no new
evidence-based therapeutic approaches have gained
widespread recognition since the introduction of gaba-
pentinoids in the 1990s. As alreadymentioned, Table 2
lists a variety of agents or viable candidates that are
currently under investigation and that have either not
yet reached clinical trials or have progressed success-
fully to phase 1 and/or phase 2 trials.
GBP and PGB, as well as tricyclic antidepressants
(such as low-dose amitriptyline) and serotonin–
noradrenaline reuptake inhibitors (such as venlafax-
ine), thus still retain their status as first-line
treatments (Finnerup et al., 2015) (Table 1). Given their
therapeutic importance and the paucity of information
regarding their exact mechanism of action (Dolphin,
2016), the remainder of the review will discuss the
current understanding of gabapentinoid action in
the light of recent advances in the understanding of
the etiology of neuropathic pain. We have already
commented that “the most used drugs are the least well
understood.”
A. Gabapentinoids and the a2d Subunits of Voltage-
Gated Ca2+ Channels
GBP was originally used as an adjunct or monother-
apy for partial and general tonic–clonic seizures, but
was later approved as a treatment of postherpetic
neuralgia (Taylor et al., 2007). Both PGB and GBP are
used to treat various forms of neuropathic pain, in-
cluding fibromyalgia (Moore et al., 2014). Some reports
suggest they may be beneficial in postoperative pain
(Dauri et al., 2009; Clarke et al., 2012), as well as in
management of neurogenic overactive bladder (Carbone
et al., 2006) and migraine (Calandre et al., 2010;
Pizzolato et al., 2011; Cain et al., 2017). An enacarbil
derivative of GBP with improved oral bioavailability is
available (Cundy et al., 2004), and this has been
approved for use in postherpetic neuralgia and restless
legs syndrome.
Despite their structural similarity to GABA, neither
GBP nor PGB binds to GABAA or to GABAB receptors
(Lanneau et al., 2001; Moore et al., 2002; Sutton et al.,
2002; Li et al., 2011). Gabapentinoids also do not affect
GABA uptake, synthesis, or metabolism (Taylor et al.,
2007; Taylor, 2009). Gee et al. (1996) isolated and
sequenced a protein that bound GBP from porcine
brain, which was identified as the a2d-1 subunit of
voltage-gated calcium channels (VGCCs). Gabapenti-
noids are thus referred to as a2d ligands. Because
partial purification of a2d subunits increases their
apparent apparent affinity for GBP (Davies et al.,
2006), it has been suggested that the drug competes
for binding of an endogenous ligand, which may be a
small molecule such as leucine, isoleucine, or valine
(Hendrich et al., 2008).
The importance of the a2d-1 subunit for gabapenti-
noid action is supported by the observation that gaba-
pentinoid binding is reduced and inhibition of allodynia
is also lost in a R217A-a2d-1 loss-of-function mutant
mouse (Field et al., 2006). These mice do, however,
exhibit allodynia following peripheral nerve injury.
Structure activity studies of PGB analogs also identified
a correlation between a2d-binding affinity (labeled GBP
displacement) and therapeutic effectiveness (Belliotti
et al., 2005).
The a2d subunits are encoded by one of four mamma-
lian genes, CACNA2D1–CACNA2D4. Although the a2d
subunit is encoded by a single gene, it is expressed as
two individual proteins (a2 and d), which then reassem-
ble and associate with the pore-forming a subunit of the
VGCC (Dolphin, 2012b, 2013, 2016).
1. Isoforms and Structure of a2d Subunits. The four
mammalian genes, CACNA2D1, 2, 3, and 4, encode the
four known isoforms of the a2d subunit: a2d-1, a2d-2,
a2d-3, and a2d-4 (Dolphin, 2013, 2016). All isoforms
have a similar structure (Dolphin, 2012b), and a signal
sequence at the N terminus of the nascent polypeptide
directs a2d into the lumen of the endoplasmic reticu-
lum. The subunit is thus expressed extracellularly once
transported to the plasma membrane. The protein
sequence of all a2d isoforms contains a Von Willebrand
Factor A (VWA) domain that plays an important role in
protein–protein interactions. Such interactions may be
affected by a five-residue sequence comprising the
metal ion-dependent adhesion site (MIDAS) motif
(Whittaker and Hynes, 2002). The nature of a short
hydrophobic domain at the C terminus of a2d subunits
predicts that they are glycosylphosphatidylinositol an-
chored (Davies et al., 2010). Thismeans that themature
protein appears on the extracellular surface, making it
potentially susceptible to extracellular modulation
(Davies et al., 2010). However, recent data suggest that
gabapentinoids interact with a2d at an intracellular site
prior to its trafficking to the cell surface (Lana et al.,
2016). As will be discussed below, this is supported by
the observation that GBP has to gain access to the
neuronal cytoplasm via the system-L neutral amino
acid transporter to exert its action (Hendrich et al.,
2008; Biggs et al., 2014, 2015).
Another cache domain containing the RRR (triple
arginine repeat) is positioned adjacent to the VWA
domain in a2d-1. This sequence may be important for
gabapentinoid binding (Field et al., 2006). The
structure of a2d-1 is illustrated schematically in
Fig. 5A.
2. Tissue Distribution of a2d Subunits. The expres-
sion of a2d subunits is fairly ubiquitous (Gong et al.,
2001). Whereas the a2d-1 subunit is expressed in
skeletal, cardiac, and smooth muscles as well as in the
CNS, peripheral nervous system, and endocrine tissues,
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the a2d-2 subunit is expressed predominantly in the
CNS, especially the cerebellum (Dolphin, 2012b, 2013).
Thea2d-3 subunit is expressed in the CNS,whereas a2d-
4 is expressed primarily in the retina and in endocrine
tissues. In neurons, the a2d-1 transcript preferentially
colocalizes with excitatory neurons, and the a2d-2
mRNA colocalizes with GABAergic inhibitory neurons
(Cole et al., 2005). This is congruent with the observa-
tion that overexpression of a2d-1 increases excitatory
synaptic transmission with minimal effect on inhibi-
tory synaptic transmission in the spinal dorsal horn
(Zhou and Luo, 2015). Gabapentin binds with greater
affinity to the a2d-1 than to the a2d-2 subunit, with no
binding affinity for a2d-3 (Marais et al., 2001).
B. a2d Subunits and Neuropathic Pain
It is now well established that a2d-1 protein expres-
sion is increased in rodent models of neuropathic pain
(Luo et al., 2002; Xiao et al., 2002; Boroujerdi et al.,
2008, 2011; Bauer et al., 2009). After nerve ligation in
nerve-injured (but not sham-operated) rats, a 17-fold
increase in the a2d-1 protein in ipsilateral L5/L6 DRGs
was observed. No increase in expression levels of other
subtypes of the a2d subunit (a2d-2, -3, and -4) following
nerve injury has been reported. Another spinal nerve
ligation study showed that injury-induced discharges
that contribute to the onset of neuropathic pain moder-
ate the expression of a2d in the spinal dorsal horn
(Boroujerdi et al., 2008, 2011). Local application of
lidocaine blocked both injury-induced discharges and
the upregulation of a2d in both dorsal spinal cord and
dorsal root ganglia.
In mice, a2d-1 gene deletion results in deficits in
behavioral signs of mechanical and cold sensitivity and
delayed mechanical hypersensitivity in response to
peripheral nerve injury (Patel et al., 2013). This corre-
lates with the observation that sensory neurons ina2d-1
knockout mice show diminished ability to generate
repetitive action potentials (Margas et al., 2016). In
addition, mice that overexpress a2d develop mechanical
allodynia similar to nerve injury models, and this has
been shown to bemediated by a presynaptic mechanism
involving an increase in excitatory synaptic transmis-
sion, as is the case with nerve injury (Nguyen et al.,
2009; Zhou and Luo, 2014, 2015). Inhibitory trans-
mission is unaffected. It is clear therefore that the
a2d-1 subunits of VGCCs play an important role in the
onset of neuropathic pain.
C. Physiologic Roles of a2d Subunits
Mutation or dysfunction of a2d subunits has been
associated with convulsive and neuropsychiatric disor-
ders as well as with night blindness and cardiovascular
dysfunction (Heyes et al., 2015; Dolphin, 2016). These
observations relate directly to the use of gabapentinoids
as anticonvulsants (Taylor et al., 2007; Offord and Isom,
2015). For the purpose of the present review, we will
focus on the physiologic role of a2d subunits as they
pertain to nociception and neuropathic pain.
1. Rapid Trafficking of Ca2+Channel a Subunits to
the Plasma Membrane. Upregulation of a2d subunits
increases the expression of Cav1 and Cav2 a subunits at
the plasma membrane as well as calcium current
density (Yasuda et al., 2004; Canti et al., 2005; Tran-
Van-Minh and Dolphin, 2010; Dolphin, 2016). The
MIDAS motif in the VWA domain of a2d-1 and a2d-2
is responsible for both effects (Canti et al., 2005; Hoppa
et al., 2012; D’Arco et al., 2015). In the case of Cav1
channels, this involves interaction with extracellular
site on the a1 subunit (Walsh et al., 2009). Altered
surface expression of Ca2+ channels has been proposed
to exert a secondary effect on mitochondrial Ca2+
buffering (D’Arco et al., 2015).
2. Slower Trafficking of Ca2+ Channel a Subunits to
Primary Afferent Terminals. In addition to controlling
trafficking of Ca2+ channel a subunits to the cell surface,
a2d subunits are thought to interact with proteins
involved in trafficking of membrane protein cargos
(Dolphin, 2012b, 2016). In the case of primary afferent
neurons, a2d is implicated in the relatively slow traf-
ficking of a subunits of HVA-Ca2+ channels from their
site of synthesis in the cell body, along primary afferent
axons, to their terminals in the spinal dorsal horn
(Bauer et al., 2009). It is tempting to speculate that
attenuation of this slow trafficking process by gabapen-
tinoids corresponds to reports of their slow onset of
action in neuropathic pain patients (Cheshire, 2002;
Stacey et al., 2008; Sharma et al., 2010), but, as
discussed in Rate of Onset of Gabapentinoid Effect, we
think this is unlikely to be the case.
3. Regulation of High-Voltage–Activated Ca2+ Chan-
nel Function. Because a2d does not affect single-
channel conductance, increases in whole-cell HVA ICa
observed following increased a2d expression may be a
consequence of more channels being inserted into
the plasma membrane (Dolphin, 2016). However,
in the case of a2d-1 effects on Cav2.2 channels in N2a
cells, the increase in current is 10-fold, whereas the
increase in protein surface expression is ,twofold
(Hoppa et al., 2012; Cassidy et al., 2014). This implies
that a2d has additional effects on channel function. In
rat DRGneurons, we found that PGB decreased the rate
of inactivation of HVA ICa (mainly Cav2.2 and Cav1.2) in
medium and small IB4+ and IB42 neurons, but not in
non-nociceptive large neurons (Biggs et al., 2014). This
is consistent with the the generalization that a2d-1 may
serve to increase the rate of inactivation (Dolphin,
2016). Further attempts to elucidate these mechanisms
in terms of voltage dependence and rate of activation
and inactivation have led to conflicting findings. This is
because the effects observed depend on which a2d
subunits–Cav channel a subunit combination is studied.
Effects may also be contingent on the presence of b
subunits (Dolphin, 2016).
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It was shown recently, however, that the post-
translational cleavage of a2d-1 into the disulfide-
linked polypeptides a2-1 and d is an essential step that
permits voltage-dependent activation of plasma mem-
brane N-type Ca2+ channels (CaV2.2), and that
uncleaved a2d inhibits native calcium currents
(Kadurin et al., 2016). These authors showed that
voltage-dependent activation of CaV2.2 channels is
promoted following cell surface proteolytic cleavage of
a2d, and that this effect was independent from the role
of a2d trafficking. Trafficking of CaV2.2 channel com-
plexes into neuronal processes was not supported by
uncleaved a2d. This mechanism may maintain imma-
ture calcium channels in an inhibited state such that
proteolytic processing of a2d permits their voltage-
dependent activation. This may allow selective traffick-
ing of mature calcium channel complexes into neuronal
processes (Kadurin et al., 2016).
Fig. 5. (A) Diagram to illustrate the essential structural features of the a2d-1 protein. (B) Diagram to illustrate slow and fast transport processes
associated with a2d-1. When levels of a2d1 are normal, its accumulation in nerve terminals is controlled by transport along primary afferent fibers
from cell bodies to the dorsal horn, a distance of about 7.5 mm in a rat. When levels of a2d-1 are elevated after nerve injury, rapid cycling in nerve
terminals over distances of ,1 mm determines level at release sites. Gabapentinoids that inhibit transport of a2d-1 thus work slowly when a2d-1 levels
are normal, but rapidly when its levels are elevated in neuropathic pain.
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4. Setting Neurotransmitter Release Probability.
Experiments on hippocampal neurons have shown that,
in addition to setting presynaptic HVA-Ca2+ channel
abundance, a2d subunits also directly control neuro-
transmitter release probability. It has been suggested
that a2d subunits configure presynaptic Ca2+ channels
to directly drive exocytosis. This process involves in-
teraction affected via theMIDAS domain on a2d (Hoppa
et al., 2012). It may be of special relevance to gabapen-
tinoid action, as their ability to control Ca2+ channel
abundancemay not fully account for its ability to control
neurotransmitter release from primary afferents (Biggs
et al., 2014).
For additional information on a2d subunits and
VGCC, see reviews by Bauer et al. (2010), Dolphin
(2012b, 2013, 2016), and Zamponi et al. (2015).
D. How Do the Gabapentinoids Work?
1. Evidence for an Intracellular Site of Action.
As already mentioned, GBP is thought to exert its
actions by entering the neuronal cytosol through the
system-L-neutral amino acid transporter prior to bind-
ing with a2d-1. Structure-activity studies have revealed
that PGB analogs that strongly bind a2d, but which are
not substrates for the transporter, lack therapeutic
efficacy (Belliotti et al., 2005). This may, however,
reflect failure of transport of the analogs into the brain.
Stronger support for an intracellular site of action
comes from the observation that GBP inhibition of
HVA ICa expressed in tsA-201 cells is prevented when
the transporter is inhibited by 2-(-)-endoamino-
bicycloheptene-2-carboxylic acid (BCH). GBP effective-
ness was also increased in Xenopus oocytes when the
system-L-neutral amino acid transporter was coex-
pressed with HVA-Ca2+ channels (Hendrich et al.,
2008). Additional support for an intracellular site of
action comes from the observation that GBP application
ipsilateral to CCI alleviates allodynia and hyperalgesia,
whereas contralateral application does not (Shahid
et al., 2017).
One potential concern with these findings is that
BCH binds to a2d-1, albeit with a 10-fold lower affinity
than GBP (Gong et al., 2001). Our recent findings argue
against the possibility that BCH prevents the effect of
GBP by attenuating its binding to a2d-1. We first
established that application of GBP for 5 days reduced
the excitability of spinal cord neurons maintained in
organotypic culture, and that this effect was blocked by
BCH (Biggs et al., 2014).We next used capsaicin to open
TRPV1 channels and showed that GBP could enter the
cytoplasm of primary afferent neurons via the open
channel pore (Biggs et al., 2015).We used thismethod of
GBP delivery to circumvent its entry via the trans-
porter. GBP delivered via TRPV1 channels decreased
spinal cord activity, but this effect was not blocked by
BCH. This indicates that the weak binding of BCH to
a2d cannot account for its ability to attenuate GBP
effects. Had this been the case, BCH would have
attenuated the effect of GBP regardless of its route of
access.
More recent work from our laboratory lends support
to the idea that gabapentinoids work intracellularly
(Alles et al., 2017). Part of this study involved in vivo
administration of GBP and study of substantia gelati-
nosa neurons ex vivo from animals that had received
GBP. These were nerve-injured animals and GBP
effectively attenuated mechanical allodynia. Compared
with controls, synaptic transmission was impaired in
spinal cord slices obtained from animals that had
received GBP, and liquid chromatography with mass
spectrometry measurements confirmed the continued
presence of the drug. Had the drug worked extracellu-
larly to block allodynia in vivo, it would have been
washed away by the time spinal cord slices were studied
and no persistent effect of the drug would be seen. This
supposition is supported by detailed quantitative argu-
ments outlined in our paper (Alles et al., 2017). These
observations are congruent with those of Lana et al.
(2016), who showed that GBP displacement of throm-
bospondin 4 binding (see below) is effected at an
intracellular site on a2d-1.
2. A Role of Thrombospondins? Thrombospondins
(TSP) 1–4 are endogenous ligands that bind to a2d-1
(Eroglu et al., 2009; Lana et al., 2016; Park et al., 2016b).
They are large extracellular matrix proteins that are
upregulated by peripheral nerve injury (Pan et al., 2015).
Because a2d-1 has been implicated in synaptogenesis
(Eroglu et al., 2009; Bauer et al., 2010), aberration of this
process following nerve injury and the actions of throm-
bospondin 4 on a2d-1 may contribute to central sensitiza-
tion (Li et al., 2014; Crosby et al., 2015; Park et al.,
2016a,b). GBPdisrupts the interaction betweena2d-1 and
the synaptogenic domain of TSP2 and thereby disrupts
synaptogenesis in vitro. It has been argued, however, that
this effect may be of limited relevance to the therapeutic
action of GBP, as any synaptic sprouting and remodelling
associated with onset of neuropathic pain would have
taken place before the initiation of therapy (Dolphin,
2016). Despite this, recent findings suggest that increased
levels of TSP4 produced by nerve injurymay contribute to
hypersensitivity of peripheral sensory systems by de-
creasingHVA ICa and increasingLVA ICa inDRGneurons
by interaction with a2d-1. These effects are blocked by
GBP (Pan et al., 2016).
3. Rapid and Slow Actions in the Spinal Dorsal
Horn. The idea that a2d participates in two types of
trafficking processes in primary afferent neurons has
already been alluded to. This idea is supported by
studies in hippocampal neurons, in which Hoppa et al.
(2012) posited that a2d subunits function through two
mechanisms: “A trafficking step from the cell soma and
a local step at the presynaptic terminal allowing
synapses to have increased exocytosis with decreased
Ca2+ influx.” We suggest that when a2d-1 levels are
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elevated, either in neuropathic pain models or by
genetic modulation (Luo et al., 2001, 2002; Bauer
et al., 2009), it is rapidly and locally trafficked from
the endoplasmic reticulum to the plasma membrane
within primary afferent nerve terminals (Bauer et al.,
2010; Alles and Smith, 2016; Alles et al., 2017). The
presence of high levels of a2d-1 in nerve terminals
facilitates interaction of the a subunits of HVA-Ca2+
channels with the neurotransmitter release machinery.
This interaction occurs via the MIDAS motif within the
VWA domain of a2d-1 (Hoppa et al., 2012).
This process is interrupted by gabapentinoids within
30 minutes of i.p. injection and accounts for the rapid
antiallodynic effect seen in nerve-injured animals
(Hunter et al., 1997; Field et al., 2006; Narita et al.,
2012; Kumar et al., 2013; Alles and Smith, 2016; Alles
et al., 2017). This idea is supported by the observation
that a rapidly developing effect of PGB in rats subject to
spared nerve injury was not associated with reduced
accumulation of a2d-1 in the superficial dorsal horn
(Yang et al., 2014a). The immunohistochemical methods
used in this paper would not distinguish between
endoplasmic reticulumand cell surface–expresseda2d-1.
By contrast, slowly developing actions of gabapenti-
noids seen in uninjured dorsal horn neurons in vitro
(Moore et al., 2002; Hendrich et al., 2012; Biggs et al.,
2014) may reflect interruption of trafficking of a2d
subunits from cell bodies to nerve terminals (Alles and
Smith, 2016). The concept of actions of gabapentinoids
on injured nerves and slower actions on uninjured
nerves is illustrated schematically in Fig. 5B.
4. Differential Effects of Gabapentinoids on Excit-
atory and Inhibitory Processes in the Substantia
Gelatinosa. As mentioned already, peripheral nerve
injury increases excitatory synaptic transmission be-
tween primary afferent fibers and excitatory neurons in
substantia gelatinosa (Balasubramanyan et al., 2006)
(Fig. 4A). These neurons usually display a delayed or
transient firing pattern in response to depolarizing
current (Yasaka et al., 2010; Punnakkal et al., 2014).
Acute treatment with GBP (Alles et al., 2017) restores
synaptic transmission to the level seen in uninjured
animals (Fig. 4A). As mentioned above, Fig. 4B shows
that nerve injury also reduces excitatory synaptic
transmission to inhibitory neurons (Balasubramanyan
et al., 2006). Inhibitory neurons in substantia gelatino-
sae usually display a tonic firing pattern in response to
depolarizing current commands (Yasaka et al., 2010).
Interestingly, GBP appears to increase excitatory drive
to inhibitory neurons (Biggs et al., 2014; Alles et al.,
2017). The mechanism of this unexpected effect, which
involves an increase in the frequency of sEPSC, remains
to be elucidated.
By contrast, GABA/glycinergic inhibitory postsynaptic
currents per se seem to be enhanced or unaffected by
GBP (Moore et al., 2002). Taken together, these actions
culminate in overall decrease in dorsal horn excitability
as judged from Ca2+ responses to 35 mM K+ (Biggs
et al., 2014; Alles et al., 2017).
Figure 3B illustrates the effect of gabapentin on the
electophysiological footprint produced in the substantia
gelatinosa by sciatic CCI. The majority of the changes
produced by gabapentin are the opposite of those seen
with CCI (Fig. 3A). Thus, GBP almost entirely elimi-
nates the electrophysiological footprint of CCI in the
substantia gelatinosa (Fig. 3C).
5. Supraspinal Actions of Gabapentinoids. In addi-
tion to its spinal actions, supraspinal mechanisms
clearly contribute to the therapeutic effects of gabapen-
tinoids (Bannister et al., 2017b). This is hardly surpris-
ing given the ubiquitous distribution of a2d subunits
throughout the nervous system (Dolphin, 2012a,b,
2013). Systemically administered GBP (100 mg/kg)
inhibits descending excitatory pronociceptive seroto-
nergic (5HT3-mediated) pathways from the brain to
spinal cord in neuropathic rats (Suzuki et al., 2005). The
effect of GBP was antagonized by a 5HT3 antagonist,
which suggests that this could be a more predominant
effect compared with a peripheral effect for an acute
mechanism of cell-type–specific action of systemically
delivered GBP. It has also been shown that GBP can
increase extracellular glutamate release in the locus
coeruleus via astrocyte-dependent mechanisms involv-
ing glutamate-transporter-1 (GLT-1; also known as
EAAT2) to activate descending noradrenergic inhibi-
tion to reduce nociception (Suto et al., 2014).
Another study using 8F-fluorodeoxyglucose-positron
emission tomography supports a central contribution to
the antiallodynic action of acute GBP (Lin et al., 2014).
It was shown that spared nerve injury induced in-
creases of glucose metabolism in thalamus, cerebellar
vermis, and medial prefrontal cortex and that these
changes were attenuated by acute GBP treatment. In
a functional magnetic resonance imaging study, acute
100 mg/kg GBP was shown to evoke changes in mul-
tiple nociceptive brain regions, including the thal-
amus and periaqueductal gray in anesthetized naive
rats (Governo et al., 2008). More recently, it was shown
that PGB can reduce neuronal hyperexcitability that
accompanies mechanical and heat-evoked responses in
the ventral posterior thalamus of spinal nerve–ligated
rats (Patel and Dickenson, 2016b). In addition, Alles
et al. (2017) demonstrated that GBP can reduce neuro-
nal hyperexcitability in the primary somatosensory
cortex immediately following systemic injection in
neuropathic rats, and that these effects correlate with
effects on synaptic transmission in the spinal dorsal
horn and antiallodynic actions of GBP.
6. Additional Sites of Gabapentinoid Action.
The ubiquitous distribution of a2d subunits throughout
the nervous system (Dolphin, 2012a,b, 2013) brings for-
ward the possibility that they interact with downstream
effectors other than the a subunits of voltage-gated Ca2+
channels. This would predict additional mechanisms of
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gabapentinoid effectiveness. For example, gabapentin
has been reported to shift the voltage dependence of
HCN4 channels to more negative potentials (Tae et al.,
2017), but may increase hyperpolarization-activated cat-
ion current in hippocampal neurons (Surges et al., 2003).
It has also been reported to interact with NMDA and
AMPA receptors, as well as KATP channels (Cheng and
Chiou, 2006). It remains to be determined whether these
actions proceed via interactions with a2d-1 or whether
other molecular processes are engaged. Some of the
interactions of gabapentinoids with ion channels may
reflect simple channel block.
E. Doses of Gabapentinoids Used in Animal Studies
and Relationship to Clinical Studies
In early studies of GBP action and interaction with
a2d, seemingly high drug concentrations of drugs were
used. For example, some of the results obtained by
Hendrich et al. (2008) used 1 mM GBP. These authors
argued that the actions of GBP may reflect antagonism
of positive modulators of a2d function, namely isoleu-
cine and leucine, which were present at 800 mM in their
culture medium, as well as valine, which was present at
400 mM. Despite this, they were also able to observe
some effects with more reasonable concentrations of
GBP (100–200 mM). We have routinely used 100 mM
gabapentin in our in vitro studies (Biggs et al., 2014,
2015; Alles and Smith, 2016; Alles et al., 2017), and this
is within the range of plasma drug concentrations
measured in patients: 70–120 (Johannessen et al.,
2003) or 34.5–127.9 mM (Berry et al., 2003).
IV. Basic Science of Gabapentinoid Action and
Observations in the Clinic
A. Inconsistency of Gabapentinoid Effectiveness
In laboratory models of neuropathic pain, every rat or
mouse that is tested responds to the antiallodynic action
of gabapentinoids (Kimura et al., 2016). This differs
from the clinical picture, in which as few as 35% of
patients report appreciable pain relief (Moore et al.,
2011). There may be many reasons for this discrepancy.
One possibility may relate to decreased clinical effec-
tiveness with time. This is frequently observed but
poorly documented (Cheshire, 2007). It is not known
whether it reflects tachyphylaxis or tolerance as a result
of repeated administration of drug or whether the pain
pathophysiology changes with time. Loss of gabapenti-
noid effectiveness has, however, been replicated in an
animal model of poststroke pain and was also seen in
animals subject to spared nerve injury (Kimura et al.,
2016; Yang et al., 2016). In the first case, this was
attributed to downregulation of a2d-1 with time despite
the persistence of pain (Yang et al., 2016). In the second
case, loss of gabapentin efficacy was associated with
downregulation of GLT-1 (better known as EAAT2) in
locus coeruleus (Kimura et al., 2016). It had been
established previously that GBP increases glutamater-
gic transmission within the locus coeruleus by a GLT-1/
EAAT2-dependent mechanism to stimulate descending
noradrenergic inhibition of spinal nociceptive circuits
(Suto et al., 2014). Interestingly, this loss of gabapenti-
noid effect in the spinal nerve ligation model could be
restored using the histone deacetylase inhibitor and
anticonvulsant agent, valproic acid (Kimura et al.,
2016). This effect was attributed to increased GLT-1/
EAAT2 expression. Other histone deacetylase inhibi-
tors such as JNJ-26481585 produce robust upregulation
of a2d-1 in mice in vivo (Capasso et al., 2015). It is
therefore possible that upregulation of a2d-1 also
contributes to the restoration of GBP effectiveness by
valproate described byKimura et al. (2016). Thismay go
along with the idea that long-term persisting neuro-
pathic pain may be a2d-1 independent, and that high
levels of a2d-1 in nerve terminals are required for
gabapentin effectiveness (Alles and Smith, 2016; Yang
et al., 2016). There is, however, a problem with the idea
that if long-term neuropathic pain is truly a2d-1 in-
dependent, why should its upregulation and its binding
to GBP have any effect at all? Nevertheless, the obvious
clinical implication is that loss or absence of gabapenti-
noid effect in the clinicmay be restored or established by
treatment with valproate, a clinically approved anti-
convulsant agent.
B. Improving Gabapeninoid Effectiveness
Another emerging approach to painmanagement is to
introduce drugs into the neuronal cytoplasm via the
open pore of TRP channels (Binshtok et al., 2007, 2009).
This may be achieved by direct activation of TRPV1 by
capsaicin or indirect activation of other drug-permeable
channels via Toll-like receptor 5 (TLR5) (Peirs and Seal,
2015; Xu et al., 2015). The TRPV1 channel pore is large
enough to permit permeation of a quaternary derivative
of lidocaine known as QX-314. This substance does not
have a local anesthetic when applied extracellularly, as
it is membrane impermeable. It is effective when
introduced into the cytoplasm via the TRPV1 channel,
and this allows selective targeting of classic C fiber
nociceptors in nociceptive pain. Because TLR5 is
expressed on medium to large A fibers, including Ab
mechanoreceptors in both mice and humans (Xu et al.,
2015), this may allow selective pharmacological block-
ade of transmission in fiber types that mediate allody-
nia. We recently noted that GBP is able to permeate
TRPV1 channels activated by capsaicin, and this led to
increased effectiveness (Biggs et al., 2015). Perhaps
topical application of GBP (Shahid et al., 2017) com-
bined with a TLR5 agonist such as flagellin (Xu et al.,
2015) may facilitate its access to a2d-1 and thereby
increase its effectiveness in the clinic.
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C. Rate of Onset of Gabapentinoid Effect
In animal models of neuropathic pain, gabapenti-
noids consistently produce an antiallodynic effect
within 30 minutes of administration (Hunter et al.,
1997; Field et al., 2006; Narita et al., 2012; Kumar et al.,
2013; Alles and Smith, 2016; Alles et al., 2017). We
contend this rapidity reflects gabapentin interaction
with upregulated a2d-1 and increased trafficking of
VGCC from endosomes to the plasmamembrane within
the confine of the nerve terminal (Fig. 5B; see Rapid
Trafficking of Ca2+ Channel a Subunits to the Plasma
Membrane). Effects of gabapentinoids in animal models
of anxiety and epilepsy are similarly rapid and are a2d-
1 mediated (Vartanian et al., 2006; Lotarski et al., 2011,
2014). Although this couldmean a2d-1 is upregulated in
these conditions, we could find no evidence to support
this. There is evidence, however, that variousmutations
in the Cacna2d2 gene that codes for a2d-2 exhibit an
epileptic phenotype.
Gabapentinoids may thus require a pathologic situa-
tion to work in neuropathic pain, but not necessarily in
epilepsy and anxiety. One possible explanation for this
is that Ca2+ channels are rapidly turning over at central
synapses involved in anxiety and epilepsy and are thus
sensitive to GBP. By contrast, Ca2+ channel turnover in
uninjured primary afferents may be relatively slow and
thus insensitive to gabapentinoids. The idea that
gabapentinoids target Ca2+ channel populations that
are rapidly turning over has been used to explain their
lack of effect on cardiac and skeletal muscle channels
(Dolphin, 2016).
Despite their rapid efficacy in animal models of
neuropathic pain (Hunter et al., 1997; Field et al.,
2006; Narita et al., 2012; Kumar et al., 2013; Alles and
Smith, 2016; Alles et al., 2017), several reports indicate
that GBP effects in clinical painmanagement take a day
or more to develop (Cheshire, 2002; Stacey et al., 2008;
Sharma et al., 2010; Rauck et al., 2013).
One factor that may contribute to this discrepancy in
time course is the difference in evaluating drug effects
in rodents and people (Yekkirala et al., 2017). Even if a
human patient exhibited an increased withdrawal
threshold to von Frey filament immediately after
GBP, it might take several days for them to state
improvement on a pain questionnaire; despite a rapid
antiallodynic effect, it may take a longer period of time
for other manifestations of neuropathic pain such as
causalgia and spontaneous pain to be altered. It should
also be noted that it is often necessary to titrate
appropriate dosage in human patients so that the
absence of obvious effectiveness may reflect the failure
to achieve an effective concentration of drug in plasma
and cerebrospinal fluid.
We therefore think it unlikely that slowly developing
action of gabapentinoids in inhibiting transport of Ca2+
channel a subunits from the cell body to nerve terminals
in animal models in vitro (Fig. 5B; see also Rapid and
Slow Actions in the Spinal Dorsal Horn) has any direct
bearing on their antiallodynic action in the clinic.
D. Animal Models of Antiallodynic Effectiveness
The discrepancy between observations in people and
in animal models may start to be addressed as more
refined models for evaluating pain are developed (Mogil
and Crager, 2004; Mogil, 2009). Indeed, recent review
has stated that current models of animal testing are
predicted to fail in modeling human pain and drug
effectiveness (Yekkirala et al., 2017). Supraspinal pro-
cessing of nociceptive information may be more akin to
the human sensation of pain than tests of mechanical,
cold, or thermal allodynia. Human pain may be better
modeled and evaluated in animals by using operant
models such as conditioned place aversion (King et al.,
2009; Zhang et al., 2015c; Bannister et al., 2017b) or
evaluation of spontaneously emitted behaviors such as
facial grimacing (Langford et al., 2010) or examination
of changes in social interaction (Mogil, 2009).
V. Conclusions
There is an urgent need to develop new pharmaceu-
tical agents for the treatment of neuropathic pain.
Extensive investigation of the etiology of neuropathic
pain has identified several potential drug targets, and
some promising new compounds are in development.
Results from clinical trials have in general been
disappointing. Many substances identified in preclini-
cal studies have failed in phase 1 or phase 2 trials
because of lack of efficacy or the presence of dose-
limiting untoward effects. Experience suggests that
highly specific agents that target one receptor or
channel never progress to the clinic, and this may
reflect the diverse etiologies of pain seen in the human
population. By contrast, drugs that interact with mul-
tiple targets such as broad-spectrum dihydropyridine
Ca2+ channel blockers (Gadotti et al., 2015)may bemore
effective. Interestingly, A3 adenosine receptor antago-
nists and gabapentinoids interact with clearly defined
targets, A3 receptors and a2d-1, yet consequences are
wide ranging. Even carbamazepine, which has been
used for many years to treat trigeminal neuralgia
(Cheshire, 2007), affects both Na+ channels and GABA
function. Ion channel function is also affected by the
noradrenaline serotonin uptake inhibitor amitriptyline
(Wolff et al., 2016), which retains its status as a first-
line treatment of neuropathic pain (Finnerup et al.,
2015; Gilron et al., 2015).
Despite their inconsistent effectiveness, gabapenti-
noids remain a first-line treatment option. Because
these drugs are expected to retain this status for the
immediate future, therapeutic management may be
improved in the light of new information regarding
their mechanism of action. Might rational combinations
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of gabapentinoids with drugs such as valproate, TLR5
agonists, or TRP channel openers improve their thera-
peutic effectiveness?
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